ORIGINAL_ARTICLE
Ancient and Novel Forms of Silver in Medicine and Biomedicine
Silver has been known and used as a potent antimicrobial and wound healing agent since ancient time. Silver compounds have had other ancient applications through which Greeks, Romans and Egyptians had used silver compounds as food and water preservative. Silver and silver-based antimicrobials were put away after the discovery of antibiotics. Meanwhile, with almost a century application of antibiotics, resistant microbial strains appeared and antibiotics are going to become less and less effective. Fortunately, our traditional weapon against microorganisms reemerged in a novel form to reclaim again. Silver nanoparticles (AgNPs) are well-known as potent and novel antimicrobial agents. AgNPs would disturb microbial growth through inhibiting the absorption of phosphate, collapsing the proton motive force, forming complexes with DNA, enzyme inactivation, as well as inhibition of glucose oxidation. Its follows attacking the respiratory chain, changing the permeability and potential of the cell membrane, and inducing bacteria into a viable but non-culturable (VBNC) state and eventually killing them.
https://jamsat.sums.ac.ir/article_42457_7fbbba613e109672318def3472ca0ef0.pdf
2016-03-01
122
128
10.18869/nrip.jamsat.2.1.122
Antimicrobial
Medicine
Silver ions
Silver Nanoparticles
Silver nitrate
Alireza
Ebrahiminezhad
a_ebrahimi@sums.ac.ir
1
Fasa University of Medical Sciences
LEAD_AUTHOR
Mohammad Javad
Raee
raeem@sums.ac.ir
2
AUTHOR
Zahra
Manafi
zmanafi@yahoo.com
3
AUTHOR
Abdolreza
Sotoodeh Jahromi
sotoodehj@yahoo.com
4
AUTHOR
Younes
Ghasemi
ghasemiy@sums.ac.ir
5
AUTHOR
Lok C-N, Ho C-M, Chen R, He Q-Y, Yu W-Y, Sun H, et al. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. Journal of Proteome research. 2006;5(4):916-24.
1
Hill WR, Pillsbury DM. Argyria: the pharmacology of silver: Williams & Wilkins Baltimore; 1939.
2
Schneider G. Silver nitrate prophylaxis. Canadian Medical Association Journal. 1984;131(3):193.
3
Clement JL, Jarrett PS. Antibacterial silver. Met Based Drugs. 1994;1(5-6):467-82.
4
Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO journal. 2000;46(6):S47-S52.
5
Klasen H. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns. 2000;26(2):117-30.
6
Silver S, Phung LT. Bacterial heavy metal resistance: new surprises. Annual Reviews in Microbiology. 1996;50(1):753-89.
7
Slawson RM, Van Dyke MI, Lee H, Trevors JT. Germanium and silver resistance, accumulation, and toxicity in microorganisms. Plasmid. 1992;27(1):72-9.
8
Ebrahiminezhad A, Barzegar Y, Ghasemi Y, Berenjian A. Green synthesis and characterization of silver nanoparticles using Alcea rosea flower extract as a new generation of antimicrobials.
9
Ebrahiminezhad A, Davaran S, Rasoul-Amini S, Barar J, Moghadam M, Ghasemi Y. Synthesis, characterization and anti-Listeria monocytogenes effect of amino acid coated magnetite nanoparticles. Curr Nanosci. 2012;8(6):868-74.
10
Ebrahiminezhad A, Ghasemi Y, Rasoul-Amini S, Barar J, Davaran S. Impact of amino-acid coating on the synthesis and characteristics of iron-oxide nanoparticles (IONs). Bull Korean Chem Soc. 2012 Dec 20;33(12):3957-62.
11
Ebrahiminezhad A, Ghasemi Y, Rasoul-Amini S, Barar J, Davaran S. Preparation of novel magnetic fluorescent nanoparticles using amino acids. Colloids Surf B. 2013 Feb 1;102:534-9.
12
Ebrahiminezhad A, Najafipour S, Kouhpayeh A, Berenjian A, Rasoul-Amini S, Ghasemi Y. Facile fabrication of uniform hollow silica microspheres using a novel biological template. Colloids Surf B. 2014;118:249-53.
13
Ebrahiminezhad A, Rasoul-Amini S, Davaran S, Barar J, Ghasemi Y. Impacts of Iron Oxide Nanoparticles on the Invasion Power of Listeria monocytogenes. Curr Nanosci. 2014;2014(10):382-8.
14
Ebrahiminezhad A, Rasoul-Amini S, Kouhpayeh A, Davaran S, Barar J, Ghasemi Y. Impacts of amine functionalized iron oxide nanoparticles on HepG2 cell line. Curr Nanosci. 2015;11(1):113-9.
15
Ebrahiminezhad A, Varma V, Yang S, Berenjian A. Magnetic immobilization of Bacillus subtilis natto cells for menaquinone-7 fermentation. Appl Microbiol Biotechnol. 2015:1-8.
16
Ebrahiminezhad A, Varma V, Yang S, Ghasemi Y, Berenjian A. Synthesis and Application of Amine Functionalized Iron Oxide Nanoparticles on Menaquinone-7 Fermentation: A Step towards Process Intensification. Nanomaterials. 2015;6(1):1.
17
Gholami A, Rasoul-amini S, Ebrahiminezhad A, Seradj SH, Ghasemi Y. Lipoamino Acid Coated Superparamagnetic Iron Oxide Nanoparticles Concentration and Time Dependently Enhanced Growth of Human Hepatocarcinoma Cell Line (Hep-G2). Journal of Nanomaterials. 2015;2015.
18
Seil JT, Webster TJ. Antimicrobial applications of nanotechnology: methods and literature. International journal of nanomedicine. 2012;7:2767.
19
Magiorakos AP, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrugâresistant, extensively drugâresistant and pandrugâresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-81.
20
Beyth N, Houri-Haddad Y, Domb A, Khan W, Hazan R. Alternative Antimicrobial Approach: Nano-Antimicrobial Materials. Evidence-Based Complementary and Alternative Medicine. 2015;2015.
21
De Simone S, Gallo A, Paladini F, Sannino A, Pollini M. Development of silver nano-coatings on silk sutures as a novel approach against surgical infections. Journal of Materials Science: Materials in Medicine. 2014;25(9):2205-14.
22
Schreurs W, Rosenberg H. Effect of silver ions on transport and retention of phosphate by Escherichia coli. Journal of Bacteriology. 1982;152(1):7-13.
23
Jung WK, Koo HC, Kim KW, Shin S, Kim SH, Park YH. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Applied and environmental microbiology. 2008;74(7):2171-8.
24
Thurman RB, Gerba CP, Bitton G. The molecular mechanisms of copper and silver ion disinfection of bacteria and viruses. Critical Reviews in Environmental Science and Technology. 1989;18(4):295-315.
25
Dibrov P, Dzioba J, Gosink KK, Häse CC. Chemiosmotic mechanism of antimicrobial activity of Ag+ in Vibrio cholerae. Antimicrobial agents and chemotherapy. 2002;46(8):2668-70.
26
Ahearn D, May L, Gabriel M. Adherence of organisms to silver-coated surfaces. Journal of industrial microbiology. 1995;15(4):372-6.
27
Richards R, Odelola H, Anderson B. Effect of silver on whole cells and spheroplasts of a silver resistant Pseudomonas aeruginosa. Microbios. 1983;39(157-158):151-7.
28
Furr J, Russell A, Turner T, Andrews A. Antibacterial activity of Actisorb Plus, Actisorb and silver nitrate. journal of Hospital Infection. 1994;27(3):201-8.
29
Rahn RO. Nondimer damage in deoxyribonucleic acid caused by ultraviolet radiation. Photochemical and photobiological reviews: Springer; 1979. p. 267-330.
30
Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. Journal of colloid and interface science. 2004;275(1):177-82.
31
Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007;73(6):1712-20.
32
Feng Q, Wu J, Chen G, Cui F, Kim T, Kim J. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res. 2000;52(4):662-8.
33
Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnology advances. 2009;27(1):76-83.
34
Gatoo MA, Naseem S, Arfat MY, Mahmood Dar A, Qasim K, Zubair S. Physicochemical properties of nanomaterials: implication in associated toxic manifestations. BioMed research international. 2014;2014.
35
Xiu Z-M, Ma J, Alvarez PJ. Differential effect of common ligands and molecular oxygen on antimicrobial activity of silver nanoparticles versus silver ions. Environ Sci Technol. 2011;45(20):9003-8.
36
Xiu Z-m, Zhang Q-b, Puppala HL, Colvin VL, Alvarez PJ. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett. 2012;12(8):4271-5.
37
Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nature Reviews Immunology. 2013;13(5):349-61.
38
Blecher K, Nasir A, Friedman A. The growing role of nanotechnology in combating infectious disease. Virulence. 2011;2(5):395-401.
39
Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Advanced drug delivery reviews. 2013;65(13):1803-15.
40
Amro NA, Kotra LP, Wadu-Mesthrige K, Bulychev A, Mobashery S, Liu G-y. High-resolution atomic force microscopy studies of the Escherichia coli outer membrane: structural basis for permeability. Langmuir. 2000;16(6):2789-96.
41
Li W-R, Xie X-B, Shi Q-S, Zeng H-Y, You-Sheng O-Y, Chen Y-B. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85(4):1115-22.
42
Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003;27(2-3):341-53.
43
Andrews JM. Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy. 2002;49(6):1049-.
44
Holt KB, Bard AJ. Interaction of silver (I) ions with the respiratory chain of Escherichia coli: an electrochemical and scanning electrochemical microscopy study of the antimicrobial mechanism of micromolar Ag+. Biochemistry. 2005;44(39):13214-23.
45
Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16(10):2346.
46
Dimitrijevic NM, Bartels DM, Jonah CD, Takahashi K, Rajh T. Radiolytically induced formation and optical absorption spectra of colloidal silver nanoparticles in supercritical ethane. J Phys Chem B. 2001;105(5):954-9.
47
Kim H-S, Lee K-H, Kim S-G. Growth of monodisperse silver nanoparticles in polymer matrix by spray pyrolysis. Aerosol Sci Technol. 2006;40(7):536-44.
48
Pal A, Shah S, Devi S. Microwave-assisted synthesis of silver nanoparticles using ethanol as a reducing agent. Mater Chem Phys. 2009;114(2):530-2.
49
Pol VG, Srivastava D, Palchik O, Palchik V, Slifkin M, Weiss A, et al. Sonochemical deposition of silver nanoparticles on silica spheres. Langmuir. 2002;18(8):3352-7.
50
Saifuddin N, Wong C, Yasumira A. Rapid biosynthesis of silver nanoparticles using culture supernatant of bacteria with microwave irradiation. Journal of Chemistry. 2009;6(1):61-70.
51
Song KC, Lee SM, Park TS, Lee BS. Preparation of colloidal silver nanoparticles by chemical reduction method. Korean J Chem Eng. 2009;26(1):153-5.
52
Starowicz M, StypuÅa B, BanaÅ J. Electrochemical synthesis of silver nanoparticles. Electrochem Commun. 2006;8(2):227-30.
53
Basavegowda N, Idhayadhulla A, Lee YR. Preparation of Au and Ag nanoparticles using Artemisia annua and their in vitro antibacterial and tyrosinase inhibitory activities. Mater Sci Eng, C. 2014;43(0):58-64.
54
Cruz D, Fale PL, Mourato A, Vaz PD, Luisa Serralheiro M, Lino ARL. Preparation and physicochemical characterization of Ag nanoparticles biosynthesized by Lippia citriodora (Lemon Verbena). Colloids Surf B. 2010;81(1):67-73.
55
Doughman SD, Krupanidhi S, Sanjeevi CB. Omega-3 fatty acids for nutrition and medicine: considering microalgae oil as a vegetarian source of EPA and DHA. Curr Diabetes Rev. 2007;3(3):198-203.
56
Dubey SP, Lahtinen M, Särkkä H, Sillanpää M. Bioprospective of Sorbus aucuparia leaf extract in development of silver and gold nanocolloids. Colloids Surf B. 2010;80(1):26-33.
57
Dubey SP, Lahtinen M, Sillanpää M. Green synthesis and characterizations of silver and gold nanoparticles using leaf extract of Rosa rugosa. Colloids Surf Physicochem Eng Aspects. 2010;364(1):34-41.
58
Dubey SP, Lahtinen M, Sillanpää M. Tansy fruit mediated greener synthesis of silver and gold nanoparticles. Process Biochem. 2010;45(7):1065-71.
59
Ghaffari-Moghaddam M, Hadi-Dabanlou R. Plant mediated green synthesis and antibacterial activity of silver nanoparticles using Crataegus douglasii fruit extract. J Ind Eng Chem. 2014;20(2):739-44.
60
He Y, Du Z, Lv H, Jia Q, Tang Z, Zheng X, et al. Green synthesis of silver nanoparticles by Chrysanthemum morifolium Ramat. extract and their application in clinical ultrasound gel. Int J Nanomedicine. 2013;8:1809-15.
61
Jean-Denis JB, Pezet R, Tabacchi R. Rapid analysis of stilbenes and derivatives from downy mildew-infected grapevine leaves by liquid chromatographyâatmospheric pressure photoionisation mass spectrometry. J Chromatogr. 2006;1112(1):263-8.
62
Kahrilas GA, Wally LM, Fredrick SJ, Hiskey M, Prieto AL, Owens JE. Microwave-assisted green synthesis of silver nanoparticles using orange peel extract. ACS Sustainable Chem Eng. 2013;2(3):367-76.
63
Lukman AI, Gong B, Marjo CE, Roessner U, Harris AT. Facile synthesis, stabilization, and anti-bacterial performance of discrete Ag nanoparticles using Medicago sativa seed exudates. J Colloid Interface Sci. 2011;353(2):433-44.
64
Mo Y-y, Tang Y-k, Wang S-y, Ling J-m, Zhang H-b, Luo D-y. Green synthesis of silver nanoparticles using eucalyptus leaf extract. Mater Lett. 2015;144:165â7.
65
Nadagouda MN, Varma RS. Green synthesis of silver and palladium nanoparticles at room temperature using coffee and tea extract. Green Chem. 2008;10(8):859-62.
66
Njagi EC, Huang H, Stafford L, Genuino H, Galindo HM, Collins JB, et al. Biosynthesis of iron and silver nanoparticles at room temperature using aqueous sorghum bran extracts. Langmuir. 2010;27(1):264-71.
67
Okafor F, Janen A, Kukhtareva T, Edwards V, Curley M. Green Synthesis of Silver Nanoparticles, Their Characterization, Application and Antibacterial Activity. Int J Env Res Public Health. 2013;10(10):5221-38.
68
Rajasekharreddy P, Rani PU. Biofabrication of Ag nanoparticles using Sterculia foetida L. seed extract and their toxic potential against mosquito vectors and HeLa cancer cells. Mater Sci Eng, C. 2014;39:203-12.
69
Reddy NJ, Nagoor Vali D, Rani M, Rani SS. Evaluation of antioxidant, antibacterial and cytotoxic effects of green synthesized silver nanoparticles by Piper longum fruit. Mater Sci Eng, C. 2014;34(0):115-22.
70
Sathishkumar M, Sneha K, Won S, Cho C-W, Kim S, Yun Y-S. Cinnamon zeylanicum bark extract and powder mediated green synthesis of nano-crystalline silver particles and its bactericidal activity. Colloids Surf B. 2009;73(2):332-8.
71
Sathishkumar M, Sneha K, Yun Y-S. Immobilization of silver nanoparticles synthesized using Curcuma longa tuber powder and extract on cotton cloth for bactericidal activity. Bioresour Technol. 2010;101(20):7958-65.
72
Å ileikaitÄ A, ProsyÄevas I, PuiÅ¡o J, Juraitis A, GuobienÄ A. Analysis of silver nanoparticles produced by chemical reduction of silver salt solution. Mater Sci-Medzg. 2006;12:287-91.
73
Song JY, Jang H-K, Kim BS. Biological synthesis of gold nanoparticles using Magnolia kobus and Diopyros kaki leaf extracts. Process Biochem. 2009;44(10):1133-8.
74
Sun Q, Cai X, Li J, Zheng M, Chen Z, Yu C-P. Green synthesis of silver nanoparticles using tea leaf extract and evaluation of their stability and antibacterial activity. Colloids Surf Physicochem Eng Aspects. 2014;444:226-31.
75
Vivekanandhan S, Schreiber M, Mason C, Mohanty AK, Misra M. Maple leaf (Acer sp.) extract mediated green process for the functionalization of ZnO powders with silver nanoparticles. Colloids Surf B. 2014;113(2014):169-75.
76
Yilmaz M, Turkdemir H, Kilic MA, Bayram E, Cicek A, Mete A, et al. Biosynthesis of silver nanoparticles using leaves of Stevia rebaudiana. Mater Chem Phys. 2011;130(3):1195-202.
77
ORIGINAL_ARTICLE
Wake-Promoting Agents; Insights into Clinical Use and Molecular Perspectives
Wake-Promoting Agents (WPAs) such as amphetamine-like stimulants or modafinil, armodafinil, methyl phenidate, caffeine and nicotine reinforce the level of vigilance through an stimulated release of neurotransmitters implicated in the arousal threshold maintenance, hence shift the drive from the sleep-promoting to wake-promoting system. The modulatory effects of WPAs on cortical activation pathways give rise to enhanced vigilance. For example, cholinergic neurons of the basal forebrain and the adenosine receptors on these neurons are agonized and antagonized by nicotine and caffeine, respectively. Caffeine similarly antagonizes adenosine receptors on the GABAergic neurons and intensifies the inhibitory drive in preoptic/anterior hypothalamus which involve in sleep induction. Modafinil however exerts its wake-promoting effects through stimulating the tuberomammillary nucleus and the hypocretinergic neurons which activate the ascending reticular activating system. Although many neutransmitter systems such as dopamine are thought to be involved upon the effects of WPAs, the empirical evidence to explain the exact mechanisms need to gain strength.
https://jamsat.sums.ac.ir/article_42459_440578a665385eeac32bfa5b8b318c91.pdf
2016-03-01
129
140
10.18869/nrip.jamsat.2.1.129
Sleepiness
Wake-promoting agents
Modafinil
Stimulants Molecular
Bijan
Zare
zare_b@sums.ac.ir
1
AUTHOR
Behrooz
Moosavi
moosavi_b@sums.ac.ir
2
AUTHOR
Mohammad
Torabi-Nami
3
Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences
LEAD_AUTHOR
Shimizu T. [Excessive daytime sleepiness (EDS)]. Nihon rinsho Japanese journal of clinical medicine. 2015;73(6):937-41.
1
Kara B, Kilic O. Predictors of poor sleep quality and excessive daytime sleepiness in Turkish adults with type 2 diabetes. Journal of clinical nursing. 2015;24(9-10):1436-9.
2
Begley KJ, Castillo S, Steinshouer CR, Malesker MA. Role of pharmacists in the treatment of excessive daytime sleepiness. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2014;29(11):741-52.
3
Fong SY, Ho CK, Wing YK. Comparing MSLT and ESS in the measurement of excessive daytime sleepiness in obstructive sleep apnoea syndrome. Journal of psychosomatic research. 2005;58(1):55-60.
4
Schreier DR, Roth C, Mathis J. Subjective perception of sleepiness in a driving simulator is different from that in the Maintenance of Wakefulness Test. Sleep medicine. 2015;16(8):994-8.
5
Tanaka H. [Multiple sleep latency test, maintenance of wakefulness test and suggestive immobilization test]. Nihon rinsho Japanese journal of clinical medicine. 2015;73(6):971-9.
6
van der Heide A, van Schie MK, Lammers GJ, Dauvilliers Y, Arnulf I, Mayer G, et al. Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. Sleep. 2015;38(7):1051-8.
7
Bioulac S, Chaufton C, Taillard J, Claret A, Sagaspe P, Fabrigoule C, et al. Excessive daytime sleepiness in adult patients with ADHD as measured by the Maintenance of Wakefulness Test, an electrophysiologic measure. The Journal of clinical psychiatry. 2015;76(7):943-8.
8
Chen Z, Wu C, Zhong M, Lyu N, Huang Z. Identification of common features of vehicle motion under drowsy/distracted driving: A case study in Wuhan, China. Accident; analysis and prevention. 2015;81:251-9.
9
Sadeghniiat-Haghighi K, Moller HJ, Saraei M, Aminian O, Khajeh-Mehrizi A. The Epworth Sleepiness Scale for screening of the drowsy driving: comparison with the maintenance of wakefulness test in an Iranian sample of commercial drivers. Acta medica Iranica. 2014;52(2):125-9.
10
Anderson C, Horne JA. Driving drowsy also worsens driver distraction. Sleep medicine. 2013;14(5):466-8.
11
Dawson J. Putting the brakes on drowsy driving. The American nurse. 2012;44(2):9.
12
Rosenberg RP. Clinical assessment of excessive daytime sleepiness in the diagnosis of sleep disorders. The Journal of clinical psychiatry. 2015;76(12):e1602.
13
Rose D, Gelaye B, Sanchez S, Castaneda B, Sanchez E, Yanez ND, et al. Morningness/eveningness chronotype, poor sleep quality, and daytime sleepiness in relation to common mental disorders among Peruvian college students. Psychology, health & medicine. 2015;20(3):345-52.
14
Haregu A, Gelaye B, Pensuksan WC, Lohsoonthorn V, Lertmaharit S, Rattananupong T, et al. Circadian rhythm characteristics, poor sleep quality, daytime sleepiness and common psychiatric disorders among Thai college students. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. 2015;7(2):182-9.
15
Suzuki K, Miyamoto M, Miyamoto T, Inoue Y, Matsui K, Nishida S, et al. The Prevalence and Characteristics of Primary Headache and Dream-Enacting Behaviour in Japanese Patients with Narcolepsy or Idiopathic Hypersomnia: A Multi-Centre Cross-Sectional Study. PloS one. 2015;10(9):e0139229.
16
Pereira D, Lopes E, da Silva Behrens NS, de Almeida Fonseca H, Sguillar DA, de Araujo Lima TF, et al. Prevalence of periodical leg movements in patients with narcolepsy in an outpatient facility in Sao Paulo. Sleep Science. 2014;7(1):69-71.
17
Heier MS, Evsiukova T, Wilson J, Abdelnoor M, Hublin C, Ervik S. Prevalence of narcolepsy with cataplexy in Norway. Acta neurologica Scandinavica. 2009;120(4):276-80.
18
Bjorvatn B, Lehmann S, Gulati S, Aurlien H, Pallesen S, Saxvig IW. Prevalence of excessive sleepiness is higher whereas insomnia is lower with greater severity of obstructive sleep apnea. Sleep & breathing = Schlaf & Atmung. 2015;19(4):1387-93.
19
Signal TL, Paine SJ, Sweeney B, Priston M, Muller D, Smith A, et al. Prevalence of abnormal sleep duration and excessive daytime sleepiness in pregnancy and the role of socio-demographic factors: comparing pregnant women with women in the general population. Sleep medicine. 2014;15(12):1477-83.
20
Liviya Ng W, Freak-Poli R, Peeters A. The prevalence and characteristics associated with excessive daytime sleepiness among Australian workers. Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine. 2014;56(9):935-45.
21
Bjorvatn B, Pallesen S, Gronli J, Sivertsen B, Lehmann S. Prevalence and correlates of insomnia and excessive sleepiness in adults with obstructive sleep apnea symptoms. Perceptual and motor skills. 2014;118(2):571-86.
22
Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep medicine. 2014;15(3):348-54.
23
Verbruggen AE, Dieltjens M, Wouters K, De Volder I, Van de Heyning PH, Braem MJ, et al. Prevalence of residual excessive sleepiness during effective oral appliance therapy for sleep-disordered breathing. Sleep medicine. 2014;15(2):269-72.
24
Vashum KP, McEvoy MA, Hancock SJ, Islam MR, Peel R, Attia JR, et al. Prevalence of and associations with excessive daytime sleepiness in an Australian older population. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health. 2015;27(2):NP2275-84.
25
Risco J, Ruiz P, Marinos A, Juarez A, Ramos M, Salmavides F, et al. Excessive sleepiness prevalence in public transportation drivers of a developing country. Traffic injury prevention. 2013;14(2):145-9.
26
Gunes Z, Sahbaz M, Tugrul E, Gunes H. Prevalence and risk factors for excessive daytime of sleepiness in rural western Anotolia (Turkey): the role of obesity and metabolic syndrome. The Southeast Asian journal of tropical medicine and public health. 2012;43(3):747-55.
27
Dunn D, Hostetler G, Iqbal M, Messina-McLaughlin P, Reiboldt A, Lin YG, et al. Wake-promoting agents: search for next generation modafinil: part I. Bioorganic & medicinal chemistry letters. 2012;22(6):2312-4.
28
Lesur B, Lin YG, Marcy VR, Aimone LD, Gruner J, Bacon ER, et al. Aryl-heteroaryl derivatives as novel wake-promoting agents. Chemical biology & drug design. 2013;81(3):429-32.
29
Louvet P, Schweizer D, Gourdel ME, Riguet E, Yue C, Marcy VR, et al. Wake-promoting agents: search for next generation modafinil: part IV. European journal of medicinal chemistry. 2012;54:949-51.
30
Dunn D, Hostetler G, Iqbal M, Marcy VR, Lin YG, Jones B, et al. Wake promoting agents: search for next generation modafinil, lessons learned: part III. Bioorganic & medicinal chemistry letters. 2012;22(11):3751-3.
31
Dunn D, Hostetler G, Iqbal M, Messina-McLaughlin P, Reiboldt A, Lin YG, et al. Wake-promoting agents: search for next generation modafinil: part II. Bioorganic & medicinal chemistry letters. 2012;22(6):2315-7.
32
Lynch J, Jr., Regan C, Stump G, Tannenbaum P, Stevens J, Bone A, et al. Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention- and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafinil, and a novel quinazolinone H3 inverse agonist. Journal of cardiovascular pharmacology. 2009;53(1):52-9.
33
Stocking EM, Letavic MA. Histamine H3 antagonists as wake-promoting and pro-cognitive agents. Current topics in medicinal chemistry. 2008;8(11):988-1002.
34
Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite. 2004;42(2):185-95.
35
Oken BS, Salinsky MC, Elsas SM. Vigilance, alertness, or sustained attention: physiological basis and measurement. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2006;117(9):1885-901.
36
Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin system. Journal of the Royal Society of Medicine. 2002;95(5):227-30.
37
McWhirter D, Bae C, Budur K. The Assessment, Diagnosis, and Treatment of Excessive Sleepiness: Practical Considerations for the Psychiatrist. Psychiatry (Edgmont). 2007;4(9):26-35.
38
Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001;21(5):1787-94.
39
Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. European journal of pharmacology. 1996;306(1-3):33-9.
40
Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. Neuropsychiatric disease and treatment. 2007;3(3):349-64.
41
Saper CB, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep. 2004;27(1):11-2.
42
Ishizuka T, Murotani T, Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neuroscience letters. 2010;483(3):193-6.
43
Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444-51.
44
Kumar R. Approved and investigational uses of modafinil : an evidence-based review. Drugs. 2008;68(13):1803-39.
45
Dauvilliers Y, Neidhart E, Billiard M, Tafti M. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. The pharmacogenomics journal. 2002;2(1):65-8.
46
Saper CB, Scammell TE. Emerging therapeutics in sleep. Annals of neurology. 2013;74(3):435-40.
47
Zaharna M, Dimitriu A, Guilleminault C. Expert opinion on pharmacotherapy of narcolepsy. Expert opinion on pharmacotherapy. 2010;11(10):1633-45.
48
Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Medical science monitor : international medical journal of experimental and clinical research. 2010;16(8):RA177-86.
49
Schwartz JR, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs. 2006;66(18):2357-70.
50
Schwartz JRL. Modafinil in the treatment of excessive sleepiness. Drug design, development and therapy. 2008;2:71-85.
51
Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs of today. 2008;44(6):395-414.
52
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Annals of neurology. 1998;43(1):88-97.
53
Edgar CJ, Pace-Schott EF, Wesnes KA. Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function. Human psychopharmacology. 2009;24(5):371-89.
54
Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular psychiatry. 2009;14(2):123-42.
55
Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep medicine reviews. 2004;8(5):339-54.
56
Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatric disease and treatment. 2008;4(3):557-66.
57
Akintomide GS, Rickards H. Narcolepsy: a review. Neuropsychiatric disease and treatment. 2011;7:507-18.
58
Cochen De Cock V, Dauvilliers Y. Current and future therapeutic approaches in narcolepsy. Future Neurology. 2011;6(6):771-82.
59
Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Archives of neurology. 1974;30(1):90-3.
60
Tunnicliff G. Sites of Action of Gamma-Hydroxybutyrate (GHB)âA Neuroactive Drug with Abuse Potential. Journal of Toxicology: Clinical Toxicology. 1997;35(6):581-90.
61
Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacological reviews. 2009;61(2):162-76.
62
Cao M, Guilleminault C. Hypocretin and its emerging role as a target for treatment of sleep disorders. Current neurology and neuroscience reports. 2011;11(2):227-34.
63
Equihua AC, De La Herran-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Frontiers in pharmacology. 2013;4:163.
64
Huang Z-L, Qu W-M, Eguchi N, Chen J-F, Schwarzschild MA, Fredholm BB, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nature neuroscience. 2005;8(7):858-9.
65
Rihel J, Schier AF. Sites of action of sleep and wake drugs: insights from model organisms. Current opinion in neurobiology. 2013;23(5):831-40.
66
Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. The Lancet Neurology. 2013;12(11):1068-75.
67
Hasan S, Pradervand S, Ahnaou A, Drinkenburg W, Tafti M, Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(7):1625-40.
68
Abbott A. Neuroscience: the molecular wake-up call. Nature. 2007;447(7143):368-70.
69
In Y, Tomoo K, Ishida T, Sakamoto Y. Crystal and molecular structure of an (S)-(+)-enantiomer of modafinil, a novel wake-promoting agent. Chemical & pharmaceutical bulletin. 2004;52(10):1186-9.
70
Choi S, Kim MY, Joo KY, Park S, Kim JA, Jung JC, et al. Modafinil inhibits K(Ca)3.1 currents and muscle contraction via a cAMP-dependent mechanism. Pharmacological research. 2012;66(1):51-9.
71
Tahsili-Fahadan P, Carr GV, Harris GC, Aston-Jones G. Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010;35(11):2203-10.
72
Mitchell HA, Bogenpohl JW, Liles LC, Epstein MP, Bozyczko-Coyne D, Williams M, et al. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacology, biochemistry, and behavior. 2008;91(2):217-22.
73
Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132(4):1027-34.
74
Xiao YL, Fu JM, Dong Z, Yang JQ, Zeng FX, Zhu LX, et al. Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta pharmacologica Sinica. 2004;25(3):301-5.
75
Lee H, Kim KC, Cho MS, Suh SH, Hong YM. Modafinil improves monocrotaline-induced pulmonary hypertension rat model. Pediatric research. 2016.
76
Kuan YC, Wu D, Huang KW, Chi NF, Hu CJ, Chung CC, et al. Effects of Modafinil and Armodafinil in Patients With Obstructive Sleep Apnea: A Meta-Analysis of Randomized Controlled Trials. Clinical therapeutics. 2016.
77
Ramachandra B. A Critical Review of Properties of Modafinil and Analytical, Bio Analytical Methods for Its Determination. Critical reviews in analytical chemistry / CRC. 2016:0.
78
Karila L, Leroy C, Dubol M, Trichard C, Mabondo A, Marill C, et al. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study with High-Resolution PET and [C]-PE2I. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2016.
79
De Ron P, Dremier S, Winlow P, Jenkins A, Hanon E, Nogueira da Costa A. Correlating behaviour and gene expression endpoints in the dopaminergic system after modafinil administration in mouse. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016.
80
Chapman JL, Vakulin A, Hedner J, Yee BJ, Marshall NS. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. The European respiratory journal. 2016.
81
Andrade C. A method for deciding about the possible safety of modafinil and armodafinil in patients with seizure disorder. The Journal of clinical psychiatry. 2016;77(1):e25-8.
82
Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016;26(2):391.
83
Hosak L, Horacek J, Beranek M, Cermakova E. Molecular heterosis in metamphetamine abusers. International journal of psychiatry in clinical practice. 2007;11(3):250-2.
84
Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotoxicity research. 2007;11(3-4):183-202.
85
Abdou MM. A molecular approach to the study of structure-activity correlation for some amphetamines. Journal of psychoactive drugs. 2001;33(3):295-300.
86
Ganjavi H, Shapiro CM. Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. The Journal of neuropsychiatry and clinical neurosciences. 2007;19(4):413-9.
87
Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715-30.
88
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437-51.
89
ORIGINAL_ARTICLE
Herbal Extract Loaded Chitosan-Based Nanofibers as a Potential Wound-Dressing
Semelil is an herbal-based compound which is used for the treatment of chronic wounds, especially diabetic foot ulcers. On the other hand, Electrospun nanofibers have many characteristics such as mimicking extracellular matrix structure, efficiency as bacterial barrier, appropriate water vapor transmission rate, and provision of adequate gaseous exchange which make them ideal candidates for wound-healing application. The aim of this study was to incorporate Semelil in electrospun nanofibers to benefit both the advantages of Semelil and electrospun nanofibers for the treatment of wounds. To this aim, the blend solution of chitosan, polyethylene oxide (PEO) and the herbal extract were electrospun and chitosan-based nanofibers loaded with the herbal extract were fabricated. The as-spun fibers were characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA). The swelling ratio and drug release behavior of the electrospun fibers were also studied. Uniform and bead-free nanofibrous mats loaded with 10-50 Wt. %extract were successfully fabricated. The FTIR spectrum indicated that the chemical nature of chitosan was not changed in the process of electrospinning. TGA analysis confirm both polymers and extract in electrospun mats. The extract loaded mats showed a high swelling ratio and a burst release of extract after 1h incubation in PBS. Mats with lower amount of drug exhibited graduate increase in the cumulative release of drug after initial burst release.
https://jamsat.sums.ac.ir/article_42455_e6b57372e429deef0324ee6e49bcf0ac.pdf
2016-03-01
141
150
10.18869/nrip.jamsat.2.1.141
electrospinning
Nanofiber
Chitosan
Melilotus officinalis extract
Esmaeil
Mirzaei
esmailmirzaei@gmail.com
1
SAMST, SUMS
AUTHOR
Saeed
Sarkar
2
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine,
Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Mahdi
Rezayat
3
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine,
Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Reza
Faridi-Majidi
refaridi@sina.tums.ac.ir
4
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine,
Tehran University of Medical Sciences, Tehran,
LEAD_AUTHOR
Larijani B, Hasani Ranjbar S. OVERVIEW OF DIABETIC FOOT; NOVEL TREATMENTS IN DIABETIC FOOT ULCER. DURO. 2008;16(1):1-6.
1
Khorram Khorshid HR, B S, Heshmat R, Abdollahi M, Salari P, Farzamfar B, et al. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARSTM). DURO. 2008;16(1):20-4.
2
Zhang Y, Lim C, Ramakrishna S, Huang Z-M. Recent development of polymer nanofibers for biomedical and biotechnological applications. J Mater Sci Mater Med. 2005;16(10):933-46.
3
Zhong SP, Zhang YZ, Lim CT. Tissue scaffolds for skin wound healing and dermal reconstruction. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2010;2(5):510-25.
4
Thakur RA, Florek CA, Kohn J, Michniak BB. Electrospun nanofibrous polymeric scaffold with targeted drug release profiles for potential application as wound dressing. Int J Pharm. 2008;364(1):87-93.
5
Lee KY, Jeong L, Kang YO, Lee SJ, Park WH. Electrospinning of polysaccharides for regenerative medicine. Adv Drug Del Rev. 2009;61(12):1020-32.
6
Faghihi F, Mirzaei E, Ai J, Lotfi A, Sayahpour FA, Barough SE, et al. Differentiation potential of human chorion-derived mesenchymal stem cells into motor neuron-like cells in two-and three-dimensional culture systems. Mol Neurobiol. 2015:1-11.
7
Jayakumar R, Prabaharan M, Nair S, Tamura H. Novel chitin and chitosan nanofibers in biomedical applications. Biotechnol Adv. 2010;28(1):142-50.
8
Taepaiboon P, Rungsardthong U, Supaphol P. Vitamin-loaded electrospun cellulose acetate nanofiber mats as transdermal and dermal therapeutic agents of vitamin A acid and vitamin E. Eur J Pharm Biopharm. 2007;67(2):387-97.
9
Taepaiboon P, Rungsardthong U, Supaphol P. Drug-loaded electrospun mats of poly (vinyl alcohol) fibres and their release characteristics of four model drugs. Nanotechnology. 2006;17(9):2317.
10
Kim K, Luu YK, Chang C, Fang D, Hsiao BS, Chu B, et al. Incorporation and controlled release of a hydrophilic antibiotic using poly (lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Controlled Release. 2004;98(1):47-56.
11
Jarusuwannapoom T, Hongrojjanawiwat W, Jitjaicham S, Wannatong L, Nithitanakul M, Pattamaprom C, et al. Effect of solvents on electro-spinnability of polystyrene solutions and morphological appearance of resulting electrospun polystyrene fibers. Eur Polym J. 2005;41(3):409-21.
12
Mit-uppatham C, Nithitanakul M, Supaphol P. Ultrafine Electrospun Polyamide-6 Fibers: Effect of Solution Conditions on Morphology and Average Fiber Diameter. Macromol Chem Phys. 2004;205(17):2327-38.
13
Zong X, Kim K, Fang D, Ran S, Hsiao BS, Chu B. Structure and process relationship of electrospun bioabsorbable nanofiber membranes. Polymer. 2002;43(16):4403-12.
14
Choi JS, Lee SW, Jeong L, Bae S-H, Min BC, Youk JH, et al. Effect of organosoluble salts on the nanofibrous structure of electrospun poly (3-hydroxybutyrate-< i> co-3-hydroxyvalerate). Int J Biol Macromol. 2004;34(4):249-56.
15
Lee JS, Choi KH, Ghim HD, Kim SS, Chun DH, Kim HY, et al. Role of molecular weight of atactic poly(vinyl alcohol) (PVA) in the structure and properties of PVA nanofabric prepared by electrospinning. J Appl Polym Sci. 2004;93(4):1638-46.
16
Demir MM, Yilgor I, Yilgor E, Erman B. Electrospinning of polyurethane fibers. Polymer. 2002;43(11):3303-9.
17
FaridiâMajidi R, Ziyadi H, Naderi N, Amani A. Use of artificial neural networks to determine parameters controlling the nanofibers diameter in electrospinning of nylonâ6, 6. J Appl Polym Sci. 2012;124(2):1589-97.
18
Ayutsede J, Gandhi M, Sukigara S, Micklus M, Chen H-E, Ko F. Regeneration of Bombyx mori silk by electrospinning. Part 3: characterization of electrospun nonwoven mat. Polymer. 2005;46(5):1625-34.
19
Zhao S, Wu X, Wang L, Huang Y. Electrospinning of ethylâcyanoethyl cellulose/tetrahydrofuran solutions. J Appl Polym Sci. 2004;91(1):242-6.
20
Lee JS, Choi KH, Ghim HD, Kim SS, Chun DH, Kim HY, et al. Role of molecular weight of atactic poly (vinyl alcohol)(PVA) in the structure and properties of PVA nanofabric prepared by electrospinning. J Appl Polym Sci. 2004;93(4):1638-46.
21
De Vasconcelos C, Bezerril dP, Dos Santos D, Dantas dT, Pereira M, Fonseca J. Effect of molecular weight and ionic strength on the formation of polyelectrolyte complexes based on poly (methacrylic acid) and chitosan. Biomacromolecules. 2006;7(4):1245-52.
22
Wan Y, Wu H, Yu A, Wen D. Biodegradable polylactide/chitosan blend membranes. Biomacromolecules. 2006;7(4):1362-72.
23
Barat R, Srinatha A, Pandit J, Anupurba S, Mittal N. Chitosan inserts for periodontitis: influence of drug loading, plasticizer and crosslinking on in vitro metronidazole release. Acta Pharm. 2007;57(4):469-77.
24
ORIGINAL_ARTICLE
Activation of the Nitric-Oxide System in Nucleus Accumbens Inhibits the Nicotine Reversal Effects upon Ethanol-Induced Amnesia
The present study investigated the possible involvement of the nucleus accumbens’ (NAc) nitric oxide system in nicotine's reversal effect upon ethanol-induced amnesia. The hypothesis was tested through ethanol state-dependent memory assessment in adult male Wistar rats. Bilateral chronic cannulae were implanted in the NAc and the animals were trained in a step-through type inhibitory avoidance memory task. The step-through latency was examined 24 h after animals’ training. The pre-training or pre-test intraperitoneal (i.p.) injection of ethanol (0.9 g/kg) decreased the step-through latency, indicating an amnesic effect of the drug. Meanwhile, the pre-test administration of ethanol (0.6 and 0.9 g/kg) could reverse the pre-training ethanol (0.9 g/kg)-induced amnesia, suggesting a state-dependent effect. Similar to ethanol, the pre-test intra-NAc microinjection of nicotine (0.25 and 0.5 µg/rat) alone or nicotine (0.1, 0.25 and 0.5 µg/mouse, intra-NAc) in combination with an ineffective dose of ethanol (0.3 g/kg) could significantly reverse the (pre-training) ethanol-induced memory impairment. The ethanol (0.9 g/kg)-induced amnesia was similarly prevented following the pre-test intra-NAc administration of a nitric oxide synthase (NOS) inhibitor, L-NAME (0.4 and 0.8 µg/rat). Of note, the co-administration of L-NAME (0.04 and 0.08 µg/rat, intra-NAc) with an ineffective dose of nicotine (0.1 µg/rat, intra- NAc) could significantly potentiate the memory-improving effect of nicotine on ethanol-induced amnesia and resembled the effects of pre-test administration of a higher dose of nicotine. Furthermore, while the pre-test intra-NAc injection of L-NAME impaired the memory retrieval by itself, the pre-test intra-NAc administration of L-arginine, a nitric oxide precursor (0.3 and 0.6 µg/rat, intra-NAc), did not exert any effect either alone or in combination with an effective dose of nicotine (0.5 µg/rat, intra-NAc) on pre-training ethanol-induced memory impairment. Our findings indicated a possible role of the nucleus accumbens’ nitric oxide system in the improving effects of nicotine on ethanol-induced amnesia and the related state-dependent learning.
https://jamsat.sums.ac.ir/article_42460_d7d9f21db1ed27c4ca97aefc7922032b.pdf
2016-03-01
151
161
10.18869/nrip.jamsat.2.1.151
Ethanol
Nicotine
Nitric oxide
Nucleus accumbens
Inhibitory avoidance memory
Rat
Nasrin
Raoufi
1
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Lahijan Branch, Lahijan
AUTHOR
Azam
Moshfegh
2
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Lahijan Branch, Lahijan
AUTHOR
Morteza
Piri
biopiri@yahoo.com
3
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Ardabil branch, Ardabil
AUTHOR
Maryam-Sadat
Shahin
4
Young Researchers’ Club, Islamic Azad University, Shahr-e-Rey Branch, Tehran, Iran
AUTHOR
Mohammad
Torabi-Nami
5
Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences
LEAD_AUTHOR
Bien TH, Burge R. Smoking and drinking: a review of the literature. Int J Addict. 1990;25(12):1429-54.
1
Batel P, Pessione F, Maitre C, Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction. 1995;90(7):977-80.
2
Larsson A, Engel JA. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev. 2004;27(8):713-20.
3
Rezayof A, Sharifi K, Zarrindast MR, Rassouli Y. Modulation of ethanol state-dependent learning by dorsal hippocampal NMDA receptors in mice. Alcohol. 2008;42(8):667-74.
4
Rezayof A, Shirazi-Zand Z, Zarrindast MR, Nayer-Nouri T. Nicotine improves ethanol-induced memory impairment: the role of dorsal hippocampal NMDA receptors. Life Sci. 2010;86(7-8):260-6.
5
Rezayof A, Zare-Chahoki A, Zarrindast MR, Rassouli Y. Inhibition of dorsal hippocampal nitric oxide synthesis potentiates ethanol-induced state-dependent memory in mice. Behav Brain Res. 2010;209(2):189-95.
6
Raoufi N, Piri M, Moshfegh A, Shahin MS. Nicotine improves ethanol-induced impairment of memory: possible involvement of nitric oxide in the dorsal hippocampus of mice. Neuroscience. 2012.
7
Rezayof A, Alijanpour S, Zarrindast MR, Rassouli Y. Ethanol state-dependent memory: involvement of dorsal hippocampal muscarinic and nicotinic receptors. Neurobiol Learn Mem. 2008;89(4):441-7.
8
Melchior CL, Glasky AJ, Ritzmann RF. A low dose of ethanol impairs working memory in mice in a win-shift foraging paradigm. Alcohol. 1993;10(6):491-3.
9
Matthews DB, Simson PE, Best PJ. Acute ethanol impairs spatial memory but not stimulus/response memory in the rat. Alcohol Clin Exp Res. 1995;19(4):902-9.
10
Chin VS, Van Skike CE, Berry RB, Kirk RE, Diaz-Granados J, Matthews DB. Effect of acute ethanol and acute allopregnanolone on spatial memory in adolescent and adult rats. Alcohol. 2011;45(5):473-83.
11
Berry RB, Matthews DB. Acute ethanol administration selectively impairs spatial memory in C57BL/6J mice. Alcohol. 2004;32(1):9-18.
12
Nakagawa Y, Iwasaki T. Involvement of benzodiazepine/GABA-A receptor complex in ethanol-induced state-dependent learning in rats. Brain Res. 1995;686(1):70-6.
13
Nakagawa Y, Iwasaki T. Ethanol-induced state-dependent learning is mediated by 5-hydroxytryptamine3 receptors but not by N-methyl-D-aspartate receptor complex. Brain Res. 1996;706(2):227-32.
14
Larsson A, Svensson L, Soderpalm B, Engel JA. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol. 2002;28(3):157-67.
15
Narahashi T, Aistrup GL, Marszalec W, Nagata K. Neuronal nicotinic acetylcholine receptors: a new target site of ethanol. Neurochem Int. 1999;35(2):131-41.
16
Lowe G. State-dependent learning effects with a combination of alcohol and nicotine. Psychopharmacology (Berl). 1986;89(1):105-7.
17
Gould TJ, Collins AC, Wehner JM. Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine Tob Res. 2001;3(1):17-24.
18
Gulick D, Gould TJ. Interactive effects of ethanol and nicotine on learning in C57BL/6J mice depend on both dose and duration of treatment. Psychopharmacology (Berl). 2008;196(3):483-95.
19
Tracy HA, Jr., Wayner MJ, Armstrong DL. Nicotine blocks ethanol and diazepam impairment of air righting and ethanol impairment of maze performance. Alcohol. 1999;18(2-3):123-30.
20
Dawson DA. Drinking as a risk factor for sustained smoking. Drug Alcohol Depend. 2000;59(3):235-49.
21
Shim I, Kim HT, Kim YH, Chun BG, Hahm DH, Lee EH, et al. Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat. Eur J Pharmacol. 2002;443(1-3):119-24.
22
Sahraei H, Falahi M, Zarrindast MR, Sabetkasaei M, Ghoshooni H, Khalili M. The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice. Eur J Pharmacol. 2004;503(1-3):81-7.
23
Schilstrom B, Mameli-Engvall M, Rawal N, Grillner P, Jardemark K, Svensson TH. Nitric oxide is involved in nicotine-induced burst firing of rat ventral tegmental area dopamine neurons. Neuroscience. 2004;125(4):957-64.
24
Piri M, Zarrindast MR. Nitric oxide in the ventral tegmental area is involved in retrieval of inhibitory avoidance memory by nicotine. Neuroscience. 2011.
25
Tayfun Uzbay I, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev. 2001;25(1):43-52.
26
Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res. 1998;54(2):321-6.
27
Martin JL, Itzhak Y. 7-Nitroindazole blocks nicotine-induced conditioned place preference but not LiCl-induced conditioned place aversion. Neuroreport. 2000;11(5):947-9.
28
Khavandgar S, Homayoun H, Zarrindast MR. The effect of L-NAME and L-arginine on impairment of memory formation and state-dependent learning induced by morphine in mice. Psychopharmacology (Berl). 2003;167(3):291-6.
29
Qiang M, Chen YC, Wang R, Wu FM, Qiao JT. Nitric oxide is involved in the formation of learning and memory in rats: studies using passive avoidance response and Morris water maze task. Behav Pharmacol. 1997;8(2-3):183-7.
30
Telegdy G, Kokavszky R. The role of nitric oxide in passive avoidance learning. Neuropharmacology. 1997;36(11-12):1583-7.
31
Zarrindast MR, Shendy MM, Ahmadi S. Nitric oxide modulates state dependency induced by lithium in an inhibitory avoidance task in mice. Behav Pharmacol. 2007;18(4):289-95.
32
Choopani S, Moosavi M, Naghdi N. Involvement of nitric oxide in insulin induced memory improvement. Peptides. 2008;29(6):898-903.
33
Kendrick KM, Guevara-Guzman R, Zorrilla J, Hinton MR, Broad KD, Mimmack M, et al. Formation of olfactory memories mediated by nitric oxide. Nature. 1997;388(6643):670-4.
34
Majlessi N, Kadkhodaee M, Parviz M, Naghdi N. Serotonin depletion in rat hippocampus attenuates L-NAME-induced spatial learning deficits. Brain Res. 2003;963(1-2):244-51.
35
Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther. 1996;276(2):460-6.
36
Blokland A, Prickaerts J, Honig W, de Vente J. State-dependent impairment in object recognition after hippocampal NOS inhibition. Neuroreport. 1998;9(18):4205-8.
37
Ingram DK, Spangler EL, Kametani H, Meyer RC, London ED. Intracerebroventricular injection of N omega-nitro-L-arginine in rats impairs learning in a 14-unit T-maze. Eur J Pharmacol. 1998;341(1):11-6.
38
Fin C, da Cunha C, Bromberg E, Schmitz PK, Bianchin M, Medina JH, et al. Experiments suggesting a role for nitric oxide in the hippocampus in memory processes. Neurobiol Learn Mem. 1995;63(2):113-5.
39
Piri M, Zarrindast MR. Nitric oxide in the ventral tegmental area is involved in retrieval of inhibitory avoidance memory by nicotine. Neuroscience. 2011;175:154-61.
40
Zarrindast MR, Piri M, Nasehi M, Ebrahimi-Ghiri M. Nitric oxide in the nucleus accumbens is involved in retrieval of inhibitory avoidance memory by nicotine. Pharmacol Biochem Behav. 2012;101(1):166-73.
41
Blokland A, de Vente J, Prickaerts J, Honig W, Markerink-van Ittersum M, Steinbusch H. Local inhibition of hippocampal nitric oxide synthase does not impair place learning in the Morris water escape task in rats. Eur J Neurosci. 1999;11(1):223-32.
42
Bannerman DM, Chapman PF, Kelly PA, Butcher SP, Morris RG. Inhibition of nitric oxide synthase does not impair spatial learning. J Neurosci. 1994;14(12):7404-14.
43
Bohme GA, Bon C, Lemaire M, Reibaud M, Piot O, Stutzmann JM, et al. Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A. 1993;90(19):9191-4.
44
Izquierdo I, Bevilaqua LR, Rossato JI, Bonini JS, Medina JH, Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci. 2006;29(9):496-505.
45
Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron. 2005;46(5):703-13.
46
Zahm DS, Heimer L. Two transpallidal pathways originating in the rat nucleus accumbens. J Comp Neurol. 1990;302(3):437-46.
47
Kalivas PW, Churchill L, Klitenick MA. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience. 1993;57(4):1047-60.
48
Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci. 1998;18(19):8003-15.
49
Gracy KN, Pickel VM. Ultrastructural localization and comparative distribution of nitric oxide synthase and N-methyl-D-aspartate receptors in the shell of the rat nucleus accumbens. Brain Res. 1997;747(2):259-72.
50
Afanas'ev I, Ferger B, Kuschinsky K. The associative type of sensitization to d-amphetamine is expressed as an NO-dependent dramatic increase in extracellular dopamine in the nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(3):232-7.
51
Oorschot DE. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol. 1996;366(4):580-99.
52
Ahmadi S, Zarrindast MR, Nouri M, Haeri-Rohani A, Rezayof A. N-Methyl-D-aspartate receptors in the ventral tegmental area are involved in retrieval of inhibitory avoidance memory by nicotine. Neurobiol Learn Mem. 2007;88(3):352-8.
53
Azizbeigi R, Ahmadi S, Babapour V, Rezayof A, Zarrindast MR. Nicotine restores morphine-induced memory deficit through the D1 and D2 dopamine receptor mechanisms in the nucleus accumbens. J Psychopharmacol. 2011;25(8):1126-33.
54
Rezayof A, Motevasseli T, Rassouli Y, Zarrindast MR. Dorsal hippocampal dopamine receptors are involved in mediating ethanol state-dependent memory. Life Sci. 2007;80(4):285-92.
55
Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience. 1998;82(3):781-9.
56
Schilstrom B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience. 1998;85(4):1005-9.
57
Paxinos G, & Watson, C. The rat brain in stereotaxic coordinatesed r, editor. San Diego: Academic Press; 1997.
58
Azami NS, Piri M, Oryan S, Jahanshahi M, Babapour V, Zarrindast MR. Involvement of dorsal hippocampal alpha-adrenergic receptors in the effect of scopolamine on memory retrieval in inhibitory avoidance task. Neurobiol Learn Mem. 2010;93(4):455-62.
59
Nasehi M, Piri M, Jamali-Raeufy N, Zarrindast MR. Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test. Physiol Behav. 2010;100(4):297-304.
60
Zarrindast MR, Eidi M, Eidi A, Oryan S. Effects of histamine and opioid systems on memory retention of passive avoidance learning in rats. Eur J Pharmacol. 2002;452(2):193-7.
61
Zarrindast MR, Farajzadeh Z, Rostami P, Rezayof A, Nourjah P. Involvement of the ventral tegmental area (VTA) in morphine-induced memory retention in morphine-sensitized rats. Behav Brain Res. 2005;163(1):100-6.
62
Davis JA, Kenney JW, Gould TJ. Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci. 2007;27(40):10870-7.
63
Manago F, Castellano C, Oliverio A, Mele A, De Leonibus E. Role of dopamine receptors subtypes, D1-like and D2-like, within the nucleus accumbens subregions, core and shell, on memory consolidation in the one-trial inhibitory avoidance task. Learn Mem. 2009;16(1):46-52.
64
Ahmadi S, Zarrindast MR, Haeri-Rohani A, Rezayof A, Nouri M. Nicotine improves morphine-induced impairment of memory: possible involvement of N-methyl-D-aspartate receptors in the nucleus accumbens. Dev Neurobiol. 2007;67(8):1118-27.
65
Criswell HE, Simson PE, Duncan GE, McCown TJ, Herbert JS, Morrow AL, et al. Molecular basis for regionally specific action of ethanol on gamma-aminobutyric acidA receptors: generalization to other ligand-gated ion channels. J Pharmacol Exp Ther. 1993;267(1):522-37.
66
Yang X, Criswell HE, Breese GR. Action of ethanol on responses to nicotine from cerebellar interneurons and medial septal neurons: relationship to methyllycaconitine inhibition of nicotine responses. Alcohol Clin Exp Res. 1999;23(6):983-90.
67
Marszalec W, Aistrup GL, Narahashi T. Ethanol-nicotine interactions at alpha-bungarotoxin-insensitive nicotinic acetylcholine receptors in rat cortical neurons. Alcohol Clin Exp Res. 1999;23(3):439-45.
68
Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20(2):92-8.
69
McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269(5231):1692-6.
70
Harooni HE, Naghdi N, Sepehri H, Rohani AH. The role of hippocampal nitric oxide (NO) on learning and immediate, short- and long-term memory retrieval in inhibitory avoidance task in male adult rats. Behav Brain Res. 2009;201(1):166-72.
71
Baratti CM, Boccia MM, Blake MG, Acosta GB. Reactivated memory of an inhibitory avoidance response in mice is sensitive to a nitric oxide synthase inhibitor. Neurobiol Learn Mem. 2008;89(4):426-40.
72
Pitsikas N, Rigamonti AE, Bonomo SM, Cella SG, Muller EE. Molsidomine antagonizes L-NAME-induced acquisition deficits in a recognition memory task in the rat. Pharmacol Res. 2003;47(4):311-5.
73
Cobb BL, Ryan KL, Frei MR, Guel-Gomez V, Mickley GA. Chronic administration of L-NAME in drinking water alters working memory in rats. Brain Res Bull. 1995;38(2):203-7.
74
Heimer L, Alheid GF, de Olmos JS, Groenewegen HJ, Haber SN, Harlan RE, et al. The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci. 1997;9(3):354-81.
75
Johnson SW, Mercuri NB, North RA. 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci. 1992;12(5):2000-6.
76
Leone P, Pocock D, Wise RA. Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol Biochem Behav. 1991;39(2):469-72.
77
Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav Neurosci. 1997;111(6):1324-34.
78
Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: effects of lesions of various CNS sites. Behav Neurosci. 1997;111(6):1313-23.
79
Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res. 2001;121(1-2):189-97.
80
Hefco V, Yamada K, Hefco A, Hritcu L, Tiron A, Nabeshima T. Role of the mesotelencephalic dopamine system in learning and memory processes in the rat. Eur J Pharmacol. 2003;475(1-3):55-60.
81
Seamans JK, Floresco SB, Phillips AG. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J Neurosci. 1998;18(4):1613-21.
82
Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev. 2003;41(2-3):268-87.
83
Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393(1-3):295-314.
84
Yang Y, Cao J, Xiong W, Zhang J, Zhou Q, Wei H, et al. Both stress experience and age determine the impairment or enhancement effect of stress on spatial memory retrieval. J Endocrinol. 2003;178(1):45-54.
85
ORIGINAL_ARTICLE
Evaluation of Gaseous Pollutants Emission Rate from Marvdasht Landfills
Unmanaged gasses emitted from the landfills can lead to various environmental and health problems for the resident of such regions. Despite various studies conducted on prediction of emission rates of gaseous pollutant in landfills, no study in currently being conducted on the emission rates of carbon dioxide, methane, and non-methane organic compounds from the Marvdasht landfills. In the first steps of this study the required information were gathered first and then the necessary prediction calculations were handled by the LandGEM software. The study results suggest that the within the years of 2003 and 2031, the generation rates of carbon dioxide, methane and non-methane organic compounds will respectively be equal to 14×1011, 4667×107 and 3.89×105 tons. Among the aforementioned gasses, in case of converting the methane energy capacity into the electrical energy, a total income of 1489 billion rials is achievable from the Marvdasht landfill within a course of 27 years of operation. However, it should be noted that no investigation was conducted on the initial and operation costs in this study. In this study, by calculating all of the required information for the design and construction of a biogas collection and extraction system in the landfill of Marvdasht, the necessary means for the appliance of such plan has been provided.
https://jamsat.sums.ac.ir/article_42462_6f131d4dc20c99ab2447fc6c0fbfbf78.pdf
2016-03-01
162
175
10.18869/nrip.jamsat.2.1.162
Landfill
Gaseous pollutants
Methane
Carbon dioxide
NMOCs
Marvdasht
Amirreza
Talaiekhozani
amirtkh@yahoo.com
1
Department of Civil Engineering, Jami Institute of Technology, Isfahan, Iran
LEAD_AUTHOR
Bahman
Masomi
2
PhD Student, School of Post-Graduate Studies, Islamic Azad University,
Bushehr Branch, Bushehr, Iran
AUTHOR
Seyed Mohammad Javad
Hashemi
3
Department of Civil Engineering, Jami Institute of Technology, Isfahan, Iran
AUTHOR
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
1
Uflacker R, Schonholz C, Papamitisakis N, trial S. Interim report of the SENTIS trial: cerebral perfusion augmentation via partial aortic occlusion in acute ischemic stroke. The Journal of cardiovascular surgery. 2008;49(6):715-21.
2
Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health technology assessment. 2002;6(26):1-112.
3
Beraki S, Litrus L, Soriano L, Monbureau M, To LK, Braithwaite SP, et al. A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke. PloS one. 2013;8(7):e69233.
4
Chen J, Shehadah A, Pal A, Zacharek A, Cui X, Cui Y, et al. Neuroprotective effect of human placenta-derived cell treatment of stroke in rats. Cell transplantation. 2013;22(5):871-9.
5
Chieffo R, Inuggi A, Straffi L, Coppi E, Gonzalez-Rosa J, Spagnolo F, et al. Mapping early changes of cortical motor output after subcortical stroke: a transcranial magnetic stimulation study. Brain stimulation. 2013;6(3):322-9.
6
Peruzzotti-Jametti L, Cambiaghi M, Bacigaluppi M, Gallizioli M, Gaude E, Mari S, et al. Safety and efficacy of transcranial direct current stimulation in acute experimental ischemic stroke. Stroke; a journal of cerebral circulation. 2013;44(11):3166-74.
7
Hossmann KA. Pathophysiology and therapy of experimental stroke. Cellular and molecular neurobiology. 2006;26(7-8):1057-83.
8
Rodrigo R, Fernandez-Gajardo R, Gutierrez R, Matamala JM, Carrasco R, Miranda-Merchak A, et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS & neurological disorders drug targets. 2013;12(5):698-714.
9
Shah K, Abbruscato T. The role of blood-brain barrier transporters in pathophysiology and pharmacotherapy of stroke. Current pharmaceutical design. 2014;20(10):1510-22.
10
Winship IR, Armitage GA, Ramakrishnan G, Dong B, Todd KG, Shuaib A. Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2014;34(1):61-71.
11
Yadollahikhales G, Borhani-Haghighi A, Torabi-Nami M, Edgell R, Cruz-Flores S. Flow Augmentation in Acute Ischemic Stroke. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2014.
12
Liebeskind DS. Collateral circulation. Stroke; a journal of cerebral circulation. 2003;34(9):2279-84.
13
Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke; a journal of cerebral circulation. 2007;38(3):948-54.
14
Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, et al. Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke; a journal of cerebral circulation. 2011;42(3):693-9.
15
Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. The Lancet Neurology. 2011;10(10):909-21.
16
Hillis AE, Ulatowski JA, Barker PB, Torbey M, Ziai W, Beauchamp NJ, et al. A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular diseases. 2003;16(3):236-46.
17
Terpolilli NA, Kim SW, Thal SC, Kataoka H, Zeisig V, Nitzsche B, et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circulation research. 2012;110(5):727-38.
18
Pranevicius O, Pranevicius M, Liebeskind DS. Partial aortic occlusion and cerebral venous steal: venous effects of arterial manipulation in acute stroke. Stroke; a journal of cerebral circulation. 2011;42(5):1478-81.
19
Levi H, Schoknecht K, Prager O, Chassidim Y, Weissberg I, Serlin Y, et al. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model. PloS one. 2012;7(6):e39636.
20
Schellinger PD, Shuaib A, Kohrmann M, Liebeskind DS, Jovin T, Hammer MD, et al. Reduced mortality and severe disability rates in the SENTIS trial. AJNR American journal of neuroradiology. 2013;34(12):2312-6.
21
Shuaib A, Schwab S, Rutledge JN, Starkman S, Liebeskind DS, Bernardini GL, et al. Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial. Journal of neurointerventional surgery. 2013;5 Suppl 1:i21-4.
22
Leker RR, Molina C, Cockroft K, Liebeskind DS, Concha M, Shuaib A, et al. Effects of age on outcome in the SENTIS trial: better outcomes in elderly patients. Cerebrovascular diseases. 2012;34(4):263-71.
23
Lutsep HL, Altafullah IM, Roberts R, Silverman IE, Turco MA, Vaishnav AG. Neurologic safety event rates in the SENTIS trial control population. Acta neurologica Scandinavica. 2013;127(2):e5-7.
24
Hammer M, Jovin T, Wahr JA, Heiss WD. Partial occlusion of the descending aorta increases cerebral blood flow in a nonstroke porcine model. Cerebrovascular diseases. 2009;28(4):406-10.
25
Cortina B, Torregrosa G, Castello-Ruiz M, Burguete MC, Moscardo A, Latorre A, et al. Improvement of the circulatory function partially accounts for the neuroprotective action of the phytoestrogen genistein in experimental ischemic stroke. European journal of pharmacology. 2013;708(1-3):88-94.
26
De Geyter D, Stoop W, Sarre S, De Keyser J, Kooijman R. Neuroprotective efficacy of subcutaneous insulin-like growth factor-I administration in normotensive and hypertensive rats with an ischemic stroke. Neuroscience. 2013;250:253-62.
27
Weston RM, Lin B, Dusting GJ, Roulston CL. Targeting oxidative stress injury after ischemic stroke in conscious rats: limited benefits with apocynin highlight the need to incorporate long term recovery. Stroke research and treatment. 2013;2013:648061.
28
Manzanero S, Santro T, Arumugam TV. Neuronal oxidative stress in acute ischemic stroke: sources and contribution to cell injury. Neurochemistry international. 2013;62(5):712-8.
29
Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2001;22(4):289-96.
30
Gu L, Wu G, Long J, Su L, Yan Y, Chen Q, et al. The role of TNF-alpha 308G>A polymorphism in the risk for ischemic stroke. The American journal of the medical sciences. 2013;345(3):227-33.
31
Akhtar M, Maikiyo AM, Najmi AK, Khanam R, Mujeeb M, Aqil M. Neuroprotective effects of chloroform and petroleum ether extracts of Nigella sativa seeds in stroke model of rat. Journal of pharmacy & bioallied sciences. 2013;5(2):119-25.
32
Bae ON, Serfozo K, Baek SH, Lee KY, Dorrance A, Rumbeiha W, et al. Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke. Stroke; a journal of cerebral circulation. 2013;44(1):205-12.
33
Sun L, Jin Y, Dong L, Sumi R, Jahan R, Li Z. The neuroprotective effects of Coccomyxa gloeobotrydiformis on the ischemic stroke in a rat model. International journal of biological sciences. 2013;9(8):811-7.
34
Dong L. QH, Zhang X., Wang C., Wang L., Cui L. Parthenolide is neuroprotective in rat experimental stroke model: downregulating NF-kappaB, phospho-p38MAPK, and caspase-1 and ameliorating BBB permeability. Mediators of inflammation. 2013:370804.
35
Zhang J, Fu B, Zhang X, Chen L, Zhang L, Zhao X, et al. Neuroprotective effect of bicyclol in rat ischemic stroke: down-regulates TLR4, TLR9, TRAF6, NF-kappaB, MMP-9 and up-regulates claudin-5 expression. Brain research. 2013;1528:80-8.
36
Yu L, Chen C, Wang LF, Kuang X, Liu K, Zhang H, et al. Neuroprotective effect of kaempferol glycosides against brain injury and neuroinflammation by inhibiting the activation of NF-kappaB and STAT3 in transient focal stroke. PloS one. 2013;8(2):e55839.
37
Godinez-Rubi M R-MA, Ortuno-Sahagun D. . Nitric oxide donors as neuroprotective agents after an ischemic stroke-related inflammatory reaction. Oxidative medicine and cellular longevity. 2013:297357.
38
Qi Z, Liu W, Luo Y, Ji X, Liu KJ. Normobaric hyperoxia-based neuroprotective therapies in ischemic stroke. Medical gas research. 2013;3(1):2.
39
Ladurner G, Kalvach P, Moessler H, Cerebrolysin Study G. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of neural transmission. 2005;112(3):415-28.
40
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia I. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke; a journal of cerebral circulation. 2012;43(3):630-6.
41
Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry. 1994;27(1):32-40.
42
Hochstein-Mintzel V, Riedemann S, Alonso O, Niedda M, Aguilar M, Reinhardt G, et al. (There will exist no interdependence between bovine leukosis and infectious bovine rhinotracheitis). Zentralblatt fur Veterinarmedizin Reihe B Journal of veterinary medicine Series B. 1986;33(3):161-5.
43
Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2013;1:CD008900.
44
Chen CL, Young SH, Gan HH, Singh R, Lao AY, Baroque AC, 2nd, et al. Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke; a journal of cerebral circulation. 2013;44(8):2093-100.
45
Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovascular diseases. 2013;35 Suppl 1:1-7.
46
Chen CL, Venketasubramanian N, Lee CF, Wong KS, Bousser MG, Investigators CS. Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study. Stroke; a journal of cerebral circulation. 2013;44(12):3580-3.
47
Bavarsad Shahripour R, Hemati A, Hosseinzadeh Maleki A. A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke. Chinese journal of integrative medicine. 2014;20(11):812-7.
48
Vafaee F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK. Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats. Neural regeneration research. 2012;7(27):2085-91.
49
Zhou Z, Lu T, Xu G, Yue X, Zhu W, Ma M, et al. Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2011;49(2):185-9.
50
ORIGINAL_ARTICLE
More Precise Mapping of Gliobalstoma Based on a Nanoprobe-Decorated Drug Molecule
Glioblastoma is considered as the most aggressive type of gliomas. Its invasive character involves adjacent tissues and hinders the treatment procedure. Although surgical resection followed by radiotherapy and chemotherapy have been the standard therapeutic protocol, the incompetency of detection methods to delineate the exact tumor margins results in recurrence of the tumor. NKCC1 (Sodium-Potassium-Chloride Cotransporter) is a transmembrane channel, which overexpress in pathological conditions like glioma and helps the tumor cells to change their shape for easier migration. Such a channel can play the role of a specific marker for infiltrating tumor cells and using a paired moiety against this transporter may possibly improve the precision of detection methods including Magnetic Resonance Imaging (MRI) contrast agents like SPNs (Superparamagnetic nanoparticles). Bumetanide, under the trade name of Bumex, is a diuretic drug that can block NKCC1. It has been demonstrated that in in-vivo context, bumetanide have the potency to decrease the migration of glioma cells. We have hypothesized that bumetanide can pair with NKCC1 and accumulate around the glioma cells. Hence, it seems that MRI contrast agents loaded with bumex on their surface can be proposed for more accurate tumor margins detection whilst providing additional therapeutic effects. The proposed theranostic nanostructure may further be improved and tested both in-vitro and in-vivo to prove its applicability.
https://jamsat.sums.ac.ir/article_42456_908675b45b031ccd21da0cc5e37027e2.pdf
2016-03-01
176
180
10.18869/nrip.jamsat.2.1.176
Bumetanide
NKCC1 (Sodium-Potassium-Chloride Cotransporter)
SPNs (Superparamagnetic nanoparticles)
Seyedeh Sara
Esnaashari
sara.esnaashari@gmail.com
1
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Samira
Raminfard
rf_samira@gmail.com
2
Department of Neuroscience and addiction studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Zeinab
Gharaylou
zeinab.gharaylou@gmail.com
3
Department of Neuroscience and addiction studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Simzar
Hosseinzadeh
s_hosseinzadeh@razi.tums.ac.ir
4
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis. 2006;1:97-117.http://dx.doi.org/10.1146/annurev.pathol.1.110304.100043
1
Verkhratsky A, Butt AM. Glial neurobiology: John Wiley & Sons; 2007.
2
Lemasson B, Galban CJ, Boes JL, Li Y, Zhu Y, Heist KA, et al. Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis. Transl Oncol. 2013;6(5):554-61.http://dx.doi.org/10.1593/tlo.13532
3
Deviers A, Ken S, Filleron T, Rowland B, Laruelo A, Catalaa I, et al. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2014;90(2):385-93. Epub 2014/08/12.http://dx.doi.org/10.1016/j.ijrobp.2014.06.009
4
Lassman AB. Molecular biology of gliomas. Current neurology and neuroscience reports. 2004;4(3):228-33.http://dx.doi.org/10.1007/s11910-004-0043-3
5
Unkelbach J, Menze BH, Konukoglu E, Dittmann F, Ayache N, Shih HA. Radiotherapy planning for glioblastoma based on a tumor growth model: implications for spatial dose redistribution. Phys Med Biol. 2014;59(3):771.http://dx.doi.org/10.1088/0031-9155/59/3/747
6
Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67(2):275-82.http://dx.doi.org/10.1002/(SICI)1097-0215(19960717)67:23.0.CO;2-9
7
Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84(3):359-69.http://dx.doi.org/10.1016/S0092-8674(00)81280-5
8
Haas BR, Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res. 2010;70(13):5597-606.http://dx.doi.org/10.1158/0008-5472.CAN-09-4666
9
Mercado A, Mount DB, Gamba G. Electroneutral cation-chloride cotransporters in the central nervous system. Neurochem Res. 2004;29(1):17-25.http://dx.doi.org/10.1023/B:NERE.0000010432.44566.21
10
Kaplan MR, Mount DB, Delpire E, Gamba G, Hebert SC. Molecular mechanisms of NaCl cotransport. Annu Rev Physiol. 1996;58(1):649-58.http://dx.doi.org/10.1146/annurev.ph.58.030196.003245
11
Becker M, Nothwang HG, Friauf E. Differential expression pattern of chloride transporters NCC, NKCC2, KCC1, KCC3, KCC4, and AE3 in the developing rat auditory brainstem. Cell Tissue Res. 2003;312(2):155-65.http://dx.doi.org/10.1007/s00441-003-0713-5
12
Raouf R, Quick K, Wood JN. Pain as a channelopathy. J Clinical Invest. 2010;120(11):3745.http://dx.doi.org/10.1172/JCI43158
13
Chen H, Sun D. The role of NaâKâCl coâtransporter in cerebral ischemia. Neurol Res. 2005;27(3):280-6.http://dx.doi.org/http://dx.doi.org/10.1179/016164105X25243
14
Ernest NJ, Sontheimer H. Extracellular glutamine is a critical modulator for regulatory volume increase in human glioma cells. Brain Res. 2007;1144:231-8.http://dx.doi.org/10.1016/j.brainres.2007.01.085
15
Habela CW, Ernest NJ, Swindall AF, Sontheimer H. Chloride accumulation drives volume dynamics underlying cell proliferation and migration. J Neurophysiol. 2009;101(2):750-7.http://dx.doi.org/10.1152/jn.90840.2008
16
Garzon-Muvdi T, Schiapparelli P, ap Rhys C, Guerrero-Cazares H, Smith C, Kim D-H, et al. Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. PLoS Biol. 2012;10(5):1070.http://dx.doi.org/10.1371/journal.pbio.1001320
17
Gamba G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol Rev. 2005;85(2):423-93.http://dx.doi.org/10.1152/physrev.00011.2004
18
Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, Hashemi Fesharaki SS, Gharakhani M, Mostafavi H, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013;54(1):9-12.http://dx.doi.org/10.1111/j.1528-1167.2012.03654.x
19
Wu W, Wu Z, Yu T, Jiang C, Kim W-S. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015;16(2):023501.http://dx.doi.org/10.1088/1468-6996/16/2/023501
20
Benz M. Superparamagnetism: theory and applications. Discussion. 2012.
21
Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010;1.http://dx.doi.org/10.3402/nano.v1i0.5358
22
Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nature Mater. 2014;13(2):125-38.http://dx.doi.org/10.1038/nmat3780
23
Wang Y, Ng YW, Chen Y, Shuter B, Yi J, Ding J, et al. Formulation of superparamagnetic iron oxides by nanoparticles of biodegradable polymers for magnetic resonance imaging. Adv Funct Mater. 2008;18(2):308-18.http://dx.doi.org/10.1002/adfm.200700456
24
Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 2005;21(19):8858-64.http://dx.doi.org/10.1021/la0503451
25
Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, Biodistribution, and DrugâDelivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small. 2010;6(16):1794-805.http://dx.doi.org/10.1002/smll.201000538
26
ORIGINAL_ARTICLE
Theoretical Tinnitus Multimodality Framework: A Neurofunctional Model
Our knowledge about subjective tinnitus physiopathology has improved in the last decades, while information to understand the main mechanisms that transform a neutral phantom sound to tinnitus distress appear to be inadequate. The current review presents evidence from several studies using neuroimaging, electrophysiology and brain lesion techniques aiming at hypothesizing a new realistic multimodality tinnitus framework which can better explain the structural and functional brain connectivity in different stages of tinnitus development. Further to the present work, a full review of the entire literature should be prompted to discuss evidence to more comprehensively investigate the relationship between structural and functional connectivity of tinnitus. Progresses in such framework will shed lights to the tinnitus neurofunctional model and further evidence-based treatment modalities.
https://jamsat.sums.ac.ir/article_42461_752eb0914813911ab848280710676116.pdf
2016-03-01
181
189
10.18869/nrip.jamsat.2.1.181
Tinnitus
Neurofunctional model
Neuroimaging
Electrophysiology
Functional Connectivity
Structural Connectivity
Iman
Ghodratitoostani
1
Interunidades Bioengenharia (EESC/FMRP/IQSC), Universidade De São Paulo, São Carlos, SP, Brazil
LEAD_AUTHOR
Alexandre
C.B.Delbem
2
USP-Institute of Mathematics and Computer Science, Universidade De São Paulo, São Carlos, SP,
AUTHOR
Mohammad
Torabi-Nami
3
Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz
AUTHOR
Bahador
Makkiabadi
4
Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran
AUTHOR
Hamid
Jalilvand
5
Department of Audiology, School of Rehabilitation Sciences, Shahid Beheshti Medical Sciences University, Tehran
AUTHOR
Tanit
Ganz Sanchez
6
University of São Paulo, Medical School, São Paulo
AUTHOR
Seydell-Greenwald A, Leaver AM, Turesky TK, Morgan S, Kim HJ, Rauschecker JP. Functional MRI evidence for a role of ventral prefrontal cortex in tinnitus. Brain research. 2012;1485:22-39.
1
Seydell-Greenwald A, Raven EP, Leaver AM, Turesky TK, Rauschecker JP. Diffusion imaging of auditory and auditory-limbic connectivity in tinnitus: preliminary evidence and methodological challenges. Neural plasticity. 2014;2014:145943.
2
Rauschecker JP, Leaver AM, Mühlau M. Tuning out the noise: limbic-auditory interactions in tinnitus. Neuron. 2010;66:819-26.
3
Pinault D. The thalamic reticular nucleus: structure, function and concept. Brain research Brain research reviews. 2004;46(1):1-31.
4
Weese GD, Phillips JM, Brown VJ. Attentional orienting is impaired by unilateral lesions of the thalamic reticular nucleus in the rat. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19(22):10135-9.
5
Baldauf ZB. Dual chemoarchitectonic lamination of the visual sector of the thalamic reticular nucleus. Neuroscience. 2010;165(3):801-18.
6
Zikopoulos B, Barbas H. Circuits formultisensory integration and attentional modulation through the prefrontal cortex and the thalamic reticular nucleus in primates. Reviews in the neurosciences. 2007;18(6):417-38.
7
Shosaku A, Sumitomo I. Auditory neurons in the rat thalamic reticular nucleus. Experimental brain research Experimentelle Hirnforschung Experimentation cerebrale. 1983;49(3):432-42.
8
Yu XJ, Xu XX, Chen X, He SG, He JF. Slow Recovery From Excitation of Thalamic Reticular Nucleus Neurons. Journal of neurophysiology. 2009;101(2):980-7.
9
Kimura A, Imbe H, Donishi T, Tamai Y. Axonal projections of single auditory neurons in the thalamic reticular nucleus: implications for tonotopy-related gating function and cross-modal modulation. Eur J Neurosci. 2007;26(12):3524-35.
10
Krause M, Hoffmann WE, Hajos M. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats. Biological psychiatry. 2003;53(3):244-53.
11
Mayo JP. Intrathalamic mechanisms of visual attention. J Neurophysiol. 2009;101(3):1123-5.
12
Zikopoulos B, Barbas H. Prefrontal projections to the thalamic reticular nucleus form a unique circuit for attentional mechanisms. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26(28):7348-61.
13
Torres-Garcia ME, Solis O, Patricio A, Rodriguez-Moreno A, Camacho-Abrego I, Limon ID, et al. Dendritic morphology changes in neurons from the prefrontal cortex, hippocampus and nucleus accumbens in rats after lesion of the thalamic reticular nucleus. Neuroscience. 2012;223:429-38.
14
Churchill L, Zahm DS, Kalivas PW. The mediodorsal nucleus of the thalamus in rats--I. forebrain gabaergic innervation. Neuroscience. 1996;70(1):93-102.
15
Churchill L, Zahm DS, Duffy P, Kalivas PW. The mediodorsal nucleus of the thalamus in rats--II. Behavioral and neurochemical effects of GABA agonists. Neuroscience. 1996;70(1):103-12.
16
Zahm DS, Williams E, Wohltmann C. Ventral striatopallidothalamic projection: IV. Relative involvements of neurochemically distinct subterritories in the ventral pallidum and adjacent parts of the rostroventral forebrain. The Journal of comparative neurology. 1996;364(2):340-62.
17
O'Donnell P, Lavin A, Enquist LW, Grace AA, Card JP. Interconnected parallel circuits between rat nucleus accumbens and thalamus revealed by retrograde transynaptic transport of pseudorabies virus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1997;17(6):2143-67.
18
Kimura A, Yokoi I, Imbe H, Donishi T, Kaneoke Y. Auditory thalamic reticular nucleus of the rat: anatomical nodes for modulation of auditory and cross-modal sensory processing in the loop connectivity between the cortex and thalamus. The Journal of comparative neurology. 2012;520(7):1457-80.
19
Zikopoulos B, Barbas H. Pathways for emotions and attention converge on the thalamic reticular nucleus in primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012;32(15):5338-50.
20
Barbas H, Zikopoulos B, Timbie C. Sensory pathways and emotional context for action in primate prefrontal cortex. Biological psychiatry. 2011;69(12):1133-9.
21
Roberts LE, Eggermont JJ, Caspary DM, Shore SE, Melcher JR, Kaltenbach JA. Ringing ears: the neuroscience of tinnitus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30(45):14972-9.
22
Gu JW, Halpin CF, Nam EC, Levine RA, Melcher JR. Tinnitus, diminished sound-level tolerance, and elevated auditory activity in humans with clinically normal hearing sensitivity. J Neurophysiol. 2010;104(6):3361-70.
23
Logothetis NK. What we can do and what we cannot do with fMRI. Nature. 2008;453(7197):869-78.
24
Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nature reviews Neuroscience. 2001;2(10):685-94.
25
Seydell-Greenwald A, Leaver AM, Turesky TK, Morgan S, Kim HJ, Rauschecker JP. Functional MRI evidence for a role of ventral prefrontal cortex in tinnitus. Brain research. 2012.
26
Bar M. A cognitive neuroscience hypothesis of mood and depression. Trends in cognitive sciences. 2009;13(11):456-63.
27
Blood AJ, Zatorre RJ, Bermudez P, Evans AC. Emotional responses to pleasant and unpleasant music correlate with activity in paralimbic brain regions. Nat Neurosci. 1999;2(4):382-7.
28
Breiter HC, Aharon I, Kahneman D, Dale A, Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron. 2001;30(2):619-39.
29
Kable JW, Glimcher PW. The neurobiology of decision: consensus and controversy. Neuron. 2009;63(6):733-45.
30
Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116-24.
31
Sotres-Bayon F, Quirk GJ. Prefrontal control of fear: more than just extinction. Current opinion in neurobiology. 2010;20(2):231-5.
32
Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to action. Current medical research and opinion. 2011;27(8):1635-43.
33
Halford JB, Anderson SD. Tinnitus severity measured by a subjective scale, audiometry and clinical judgement. The Journal of laryngology and otology. 1991;105(2):89-93.
34
Halford JB, Anderson SD. Anxiety and depression in tinnitus sufferers. Journal of psychosomatic research. 1991;35(4-5):383-90.
35
Robinson S. Antidepressants for treatment of tinnitus. Prog Brain Res. 2007;166:263-71.
36
Muhlau M, Rauschecker JP, Oestreicher E, Gaser C, Rottinger M, Wohlschlager AM, et al. Structural brain changes in tinnitus. Cereb Cortex. 2006;16(9):1283-8.
37
Langguth B, Kleinjung T, Landgrebe M. Tinnitus: the complexity of standardization. Evaluation & the health professions. 2011;34(4):429-33.
38
Moller AR. Pathophysiology of tinnitus. Otolaryngol Clin North Am. 2003;36(2):249-66, v-vi.
39
Moller AR. Neural plasticity in tinnitus. Prog Brain Res. 2006;157:365-72.
40
Mahlke C, Wallhausser-Franke E. Evidence for tinnitus-related plasticity in the auditory and limbic system, demonstrated by arg3.1 and c-fos immunocytochemistry. Hear Res. 2004;195(1-2):17-34.
41
Landgrebe M, Langguth B, Rosengarth K, Braun S, Koch A, Kleinjung T, et al. Structural brain changes in tinnitus: grey matter decrease in auditory and non-auditory brain areas. NeuroImage. 2009;46(1):213-8.
42
Lanting CP, de Kleine E, van Dijk P. Neural activity underlying tinnitus generation: results from PET and fMRI. Hear Res. 2009;255(1-2):1-13.
43
Kaltenbach JA, Godfrey DA. Dorsal cochlear nucleus hyperactivity and tinnitus: are they related? American journal of audiology. 2008;17(2):S148-61.
44
Shulman A. A Final Common Pathway for Tinnitus - The Medial Temporal Lobe System. Int Tinnitus J. 1995;1(2):115-26.
45
De Ridder D, Vanneste S, Congedo M. The distressed brain: a group blind source separation analysis on tinnitus. PloS one. 2011;6(10):e24273.
46
Rauschecker JP, Leaver AM, Muhlau M. Tuning out the noise: limbic-auditory interactions in tinnitus. Neuron. 2010;66(6):819-26.
47
Divac I, Mogensen J, Marinkovic S, Martensson R. On the projections from the neostriatum to the cerebral cortex: the "displaced" neurons. Neuroscience. 1987;21(1):197-205.
48
Ferry AT, Ongur D, An X, Price JL. Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. The Journal of comparative neurology. 2000;425(3):447-70.
49
Jayaraman A. Anatomical evidence for cortical projections from the striatum in the cat. Brain research. 1980;195(1):29-36.
50
Schlee W, Mueller N, Hartmann T, Keil J, Lorenz I, Weisz N. Mapping cortical hubs in tinnitus. BMC biology. 2009;7:80.
51
LeDoux J. The amygdala. Current biology : CB. 2007;17(20):R868-74.
52
Sah P, Lopez De Armentia M. Excitatory synaptic transmission in the lateral and central amygdala. Annals of the New York Academy of Sciences. 2003;985:67-77.
53
Kraus KS, Canlon B. Neuronal connectivity and interactions between the auditory and limbic systems. Effects of noise and tinnitus. Hear Res. 2012;288(1-2):34-46.
54
Rasia-Filho AA, Londero RG, Achaval M. Functional activities of the amygdala: an overview. Journal of psychiatry & neuroscience : JPN. 2000;25(1):14-23.
55
Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48(2):175-87.
56
Davis M, Whalen PJ. The amygdala: vigilance and emotion. Molecular psychiatry. 2001;6(1):13-34.
57
Baxter MG, Murray EA. The amygdala and reward. Nature reviews Neuroscience. 2002;3(7):563-73.
58
Sander D, Grafman J, Zalla T. The human amygdala: an evolved system for relevance detection. Reviews in the neurosciences. 2003;14(4):303-16.
59
Zald DH. The human amygdala and the emotional evaluation of sensory stimuli. Brain research Brain research reviews. 2003;41(1):88-123.
60
Pessoa L. Reprint of: Emotion and cognition and the amygdala: from "what is it?" to "what's to be done?". Neuropsychologia. 2011;49(4):681-94.
61
Compton RJ. The interface between emotion and attention: a review of evidence from psychology and neuroscience. Behavioral and cognitive neuroscience reviews. 2003;2(2):115-29.
62
Compton RJ, Banich MT, Mohanty A, Milham MP, Herrington J, Miller GA, et al. Paying attention to emotion: an fMRI investigation of cognitive and emotional stroop tasks. Cognitive, affective & behavioral neuroscience. 2003;3(2):81-96.
63
Murray EA, Wise SP. What, if anything, can monkeys tell us about human amnesia when they can't say anything at all? Neuropsychologia. 2010;48(8):2385-405.
64
Murray EA. The amygdala, reward and emotion. Trends in cognitive sciences. 2007;11(11):489-97.
65
Bechara A, Damasio H, Damasio AR. Role of the amygdala in decision-making. Annals of the New York Academy of Sciences. 2003;985:356-69.
66
Balleine BW, Killcross S. Parallel incentive processing: an integrated view of amygdala function. Trends Neurosci. 2006;29(5):272-9.
67
Pessoa L. Emotion and cognition and the amygdala: from "what is it?" to "what's to be done?". Neuropsychologia. 2010;48(12):3416-29.
68
Salzman CD, Fusi S. Emotion, cognition, and mental state representation in amygdala and prefrontal cortex. Annual review of neuroscience. 2010;33:173-202.
69
Maren S. What the amygdala does and doesn't do in aversive learning. Learn Mem. 2003;10(5):306-8.
70
Maren S. Synaptic mechanisms of associative memory in the amygdala. Neuron. 2005;47(6):783-6.
71
Weinberger NM. The medial geniculate, not the amygdala, as the root of auditory fear conditioning. Hear Res. 2011;274(1-2):61-74.
72
Armony JL, Quirk GJ, LeDoux JE. Differential effects of amygdala lesions on early and late plastic components of auditory cortex spike trains during fear conditioning. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1998;18(7):2592-601.
73
Pedemonte M, Pena JL, Velluti RA. Firing of inferior colliculus auditory neurons is phase-locked to the hippocampus theta rhythm during paradoxical sleep and waking. Experimental brain research Experimentelle Hirnforschung Experimentation cerebrale. 1996;112(1):41-6.
74
Ising H, Kruppa B. Health effects caused by noise: evidence in the literature from the past 25 years. Noise & health. 2004;6(22):5-13.
75
Czisch M, Wehrle R, Stiegler A, Peters H, Andrade K, Holsboer F, et al. Acoustic oddball during NREM sleep: a combined EEG/fMRI study. PloS one. 2009;4(8):e6749.
76
Boso M, Politi P, Barale F, Enzo E. Neurophysiology and neurobiology of the musical experience. Functional neurology. 2006;21(4):187-91.
77
Limb CJ. Structural and functional neural correlates of music perception. The anatomical record Part A, Discoveries in molecular, cellular, and evolutionary biology. 2006;288(4):435-46.
78
Jentschke S, Koelsch S, Friederici AD. Investigating the relationship of music and language in children: influences of musical training and language impairment. Annals of the New York Academy of Sciences. 2005;1060:231-42.
79
Morris JS, Friston KJ, Dolan RJ. Experience-dependent modulation of tonotopic neural responses in human auditory cortex. Proceedings Biological sciences / The Royal Society. 1998;265(1397):649-57.
80
Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR. Neocortical modulation of the amygdala response to fearful stimuli. Biological psychiatry. 2003;53(6):494-501.
81
Weinberger NM. Associative representational plasticity in the auditory cortex: a synthesis of two disciplines. Learn Mem. 2007;14(1-2):1-16.
82
Froemke RC, Martins AR. Spectrotemporal dynamics of auditory cortical synaptic receptive field plasticity. Hear Res. 2011;279(1-2):149-61.
83
He DF, Chen FJ, Zhou SC. GABA mediaties the inhibitory effect of lateral amygdaloid nucleus stimulation on the acoustic response of neurons in A I cortex: An in vivo microiontophoretic study. Sheng li xue bao : [Acta physiologica Sinica]. 2004;56(3):374-8.
84
Marsh RA, Fuzessery ZM, Grose CD, Wenstrup JJ. Projection to the inferior colliculus from the basal nucleus of the amygdala. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002;22(23):10449-60.
85
Mohedano-Moriano A, Pro-Sistiaga P, Arroyo-Jimenez MM, Artacho-Perula E, Insausti AM, Marcos P, et al. Topographical and laminar distribution of cortical input to the monkey entorhinal cortex. Journal of anatomy. 2007;211(2):250-60.
86
Munoz-Lopez MM, Mohedano-Moriano A, Insausti R. Anatomical pathways for auditory memory in primates. Frontiers in neuroanatomy. 2010;4:129.
87
O'Mara S. The subiculum: what it does, what it might do, and what neuroanatomy has yet to tell us. Journal of anatomy. 2005;207(3):271-82.
88
Eichenbaum H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron. 2004;44(1):109-20.
89
DeVito LM, Eichenbaum H. Distinct contributions of the hippocampus and medial prefrontal cortex to the "what-where-when" components of episodic-like memory in mice. Behavioural brain research. 2010;215(2):318-25.
90
Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron. 2002;35(4):625-41.
91
Phelps EA. Human emotion and memory: interactions of the amygdala and hippocampal complex. Current opinion in neurobiology. 2004;14(2):198-202.
92
Richter-Levin G. The amygdala, the hippocampus, and emotional modulation of memory. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. 2004;10(1):31-9.
93
Abe K. Modulation of hippocampal long-term potentiation by the amygdala: a synaptic mechanism linking emotion and memory. Japanese journal of pharmacology. 2001;86(1):18-22.
94
Richter-Levin G, Akirav I. Amygdala-hippocampus dynamic interaction in relation to memory. Molecular neurobiology. 2000;22(1-3):11-20.
95
Watanabe T, Yagishita S, Kikyo H. Memory of music: roles of right hippocampus and left inferior frontal gyrus. NeuroImage. 2008;39(1):483-91.
96
Mitterschiffthaler MT, Fu CH, Dalton JA, Andrew CM, Williams SC. A functional MRI study of happy and sad affective states induced by classical music. Human brain mapping. 2007;28(11):1150-62.
97
Angelucci F, Fiore M, Ricci E, Padua L, Sabino A, Tonali PA. Investigating the neurobiology of music: brain-derived neurotrophic factor modulation in the hippocampus of young adult mice. Behavioural pharmacology. 2007;18(5-6):491-6.
98
Warden MR, Selimbeyoglu A, Mirzabekov JJ, Lo M, Thompson KR, Kim SY, et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature. 2012;492(7429):428-32.
99
Alvarez JA, Emory E. Executive function and the frontal lobes: a meta-analytic review. Neuropsychology review. 2006;16(1):17-42.
100
Price JL. Prefrontal cortical networks related to visceral function and mood. Annals of the New York Academy of Sciences. 1999;877:383-96.
101
Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. The Journal of comparative neurology. 1992;320(2):145-60.
102
Vertes RP. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat. Neuroscience. 2006;142(1):1-20.
103
Jay TM, Witter MP. Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgaris-leucoagglutinin. The Journal of comparative neurology. 1991;313(4):574-86.
104
Lewis DA, Anderson SA. The functional architecture of the prefrontal cortex and schizophrenia. Psychological medicine. 1995;25(5):887-94.
105
O'Donnell P, Grace AA. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1995;15(5 Pt 1):3622-39.
106
Goto Y, O'Donnell P. Network synchrony in the nucleus accumbens in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001;21(12):4498-504.
107
Silva-Gomez AB, Rojas D, Juarez I, Flores G. Decreased dendritic spine density on prefrontal cortical and hippocampal pyramidal neurons in postweaning social isolation rats. Brain research. 2003;983(1-2):128-36.
108
Kolb B, Forgie M, Gibb R, Gorny G, Rowntree S. Age, experience and the changing brain. Neurosci Biobehav Rev. 1998;22(2):143-59.
109
Leaver AM, Renier L, Chevillet MA, Morgan S, Kim HJ, Rauschecker JP. Dysregulation of limbic and auditory networks in tinnitus. Neuron. 2011;69(1):33-43.
110
Leaver AM, Seydell-Greenwald A, Turesky TK, Morgan S, Kim HJ, Rauschecker JP. Cortico-limbic morphology separates tinnitus from tinnitus distress. Frontiers in systems neuroscience. 2012;6:21.
111
Tomasi D, Caparelli EC, Chang L, Ernst T. fMRI-acoustic noise alters brain activation during working memory tasks. NeuroImage. 2005;27(2):377-86.
112
Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, et al. Neural circuitry underlying voluntary suppression of sadness. Biological psychiatry. 2003;53(6):502-10.
113
Brown P, Molliver ME. Dual serotonin (5-HT) projections to the nucleus accumbens core and shell: relation of the 5-HT transporter to amphetamine-induced neurotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2000;20(5):1952-63.
114
McCormick DA, Wang Z. Serotonin and noradrenaline excite GABAergic neurones of the guinea-pig and cat nucleus reticularis thalami. The Journal of physiology. 1991;442:235-55.
115
Pape HC, McCormick DA. Noradrenaline and serotonin selectively modulate thalamic burst firing by enhancing a hyperpolarization-activated cation current. Nature. 1989;340(6236):715-8.
116
Guillery RW, Sherman SM. Thalamic relay functions and their role in corticocortical communication: generalizations from the visual system. Neuron. 2002;33(2):163-75.
117
Llinas R, Jahnsen H. Electrophysiology of mammalian thalamic neurones in vitro. Nature. 1982;297(5865):406-8.
118
Sherman SM. A wake-up call from the thalamus. Nat Neurosci. 2001;4(4):344-6.
119
Ploghaus A, Becerra L, Borras C, Borsook D. Neural circuitry underlying pain modulation: expectation, hypnosis, placebo. Trends in cognitive sciences. 2003;7(5):197-200.
120
Drevets WC, Price JL, Simpson JR, Jr., Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824-7.
121
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-60.
122
Blood AJ, Zatorre RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci U S A. 2001;98(20):11818-23.
123
Gruber AJ, Hussain RJ, O'Donnell P. The nucleus accumbens: a switchboard for goal-directed behaviors. PloS one. 2009;4(4):e5062.
124
Johansen-Berg H, Gutman DA, Behrens TE, Matthews PM, Rushworth MF, Katz E, et al. Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex. 2008;18(6):1374-83.
125
Ongur D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex. 2000;10(3):206-19.
126
McCullough LD, Sokolowski JD, Salamone JD. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neuroscience. 1993;52(4):919-25.
127
Ambroggi F, Ishikawa A, Fields HL, Nicola SM. Basolateral amygdala neurons facilitate reward-seeking behavior by exciting nucleus accumbens neurons. Neuron. 2008;59(4):648-61.
128
Hoffman HJ, Reed GW. Epidemiology of tinnitus. Tinnitus: Theory and Management2004. p. 16e41.
129
Levine RA, Abel M, Cheng H. CNS somatosensory-auditory interactions elicit or modulate tinnitus. Experimental brain research Experimentelle Hirnforschung Experimentation cerebrale. 2003;153(4):643-8.
130
Alster J, Shemesh Z, Ornan M, Attias J. Sleep disturbance associated with chronic tinnitus. Biological psychiatry. 1993;34(1-2):84-90.
131
Folmer RL, Griest SE. Tinnitus and insomnia. Am J Otolaryngol. 2000;21(5):287-93.
132
Hallam RS. Correlates of sleep disturbance in chronic distressing tinnitus. Scandinavian audiology. 1996;25(4):263-6.
133
Kaltenbach JA. Neurophysiologic mechanisms of tinnitus. J Am Acad Audiol. 2000;11(3):125-37.
134
Eggermont JJ. Correlated neural activity as the driving force for functional changes in auditory cortex. Hear Res. 2007;229(1-2):69-80.
135
Eggermont JJ, Roberts LE. The neuroscience of tinnitus. Trends in neurosciences. 2004;27(11):676-82.
136
Norena AJ, Eggermont JJ. Changes in spontaneous neural activity immediately after an acoustic trauma: implications for neural correlates of tinnitus. Hearing research. 2003;183(1-2):137-53.
137
Kaltenbach JA, Zacharek MA, Zhang J, Frederick S. Activity in the dorsal cochlear nucleus of hamsters previously tested for tinnitus following intense tone exposure. Neurosci Lett. 2004;355(1-2):121-5.
138
Seki S, Eggermont JJ. Changes in spontaneous firing rate and neural synchrony in cat primary auditory cortex after localized tone-induced hearing loss. Hear Res. 2003;180(1-2):28-38.
139
Muhlnickel W, Elbert T, Taub E, Flor H. Reorganization of auditory cortex in tinnitus. Proc Natl Acad Sci U S A. 1998;95(17):10340-3.
140
Eggermont JJ. Cortical tonotopic map reorganization and its implications for treatment of tinnitus. Acta oto-laryngologica Supplementum. 2006(556):9-12.
141
Rajan R, Irvine DR. Neuronal responses across cortical field A1 in plasticity induced by peripheral auditory organ damage. Audiology & neuro-otology. 1998;3(2-3):123-44.
142
Langguth B, Landgrebe M, Kleinjung T, Sand GP, Hajak G. Tinnitus and depression. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2011;12(7):489-500.
143
Lenhardt ML, Shulman A, Goldstein BA. The role of the insula cortex in the final common pathway for tinnitus: experience using ultra-high-frequency therapy. Int Tinnitus J. 2008;14(1):13-6.
144
Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res. 2007;226(1-2):221-31.
145
Zenner HP, Pfister M, Birbaumer N. Tinnitus sensitization: Sensory and psychophysiological aspects of a new pathway of acquired centralization of chronic tinnitus. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2006;27:1054-63.
146
ORIGINAL_ARTICLE
Immunotherapy in Metastatic Malignant Melanoma and Non-Small Cell Lung Cancer; a Brief Review and Position Statement from the Immuno-Oncology Clinical Forum (IOCF), Iran
Given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. Immunotherapy, an approach to harness normal immune cells against cancers not only today’s breakthrough but in fact the future of oncology therapeutics. Taking into consideration the recent approvals for new lines of therapy including anti-programmed-death-1 or programmed-death-1 ligand (PD-1/PD-L1) monoclonal antibodies for the treatment of Malignant Melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC), local strategies need to be established following the field experts’ concurrence. Expert input forums are among the key approaches to define locally-adapted clinical-pathways with regard to the novel treatments. To this end, a panel of Iranian medical oncology experts reviewed the available evidence, taking into consideration recent practice guidelines with regard to the treatment of MM and NSCLC in order to draw an agreed-upon approach highlighting the position of immunotherapy in their current practice. Having addressed the key questions and considering the possible limitations and challenges, the panel could reach an agreed position. This report highlights the discussions with regards to the role of immunotherapy in MM and NSCLC during the immune-oncology clinical forum (IOCF) comprising an Iranian panel of experts.
https://jamsat.sums.ac.ir/article_42458_0d4d0041b9f33c57adb01ad9b9ae0081.pdf
2016-03-01
190
196
10.18869/nrip.jamsat.2.1.190
immunotherapy
Malignant melanoma
NSCLC
PD-1/PDL-1
Oncology
Iran
Arafat
Tfayli
at35@aub.edu.lb
1
NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut
AUTHOR
Hamid
Attarian
2
Department of Hematology-Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mojtaba
Ghadyani
3
Department of Hematology-Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Atabak
Ghotb
a_ghotb@behestandarou.com
4
Behphar Scientific Committee, Behphar Group, Tehran, Iran
AUTHOR
Mehrdad
Mashadian
5
Hematology-Oncology Division, Atieh Hospital, Tehran, Iran
AUTHOR
Babak
Salimi
6
Department of Hematology-Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Sadegh
Sedaghat
7
Department of Hematology-Oncology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
AUTHOR
Mohammad
Seghatoleslami
8
Department of Hematology-Oncology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Sharareh
Seifi
9
Department of Hematology-Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad
Torabi-Nami
10
Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Flati V, Corsetti G, Pasini E, Rufo A, Romano C, Dioguardi FS. Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths? Anti-cancer agents in medicinal chemistry. 2015;16(1):89-100.
1
Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). Journal of geriatric oncology. 2015;6(4):272-279.
2
Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Current drug safety. 2015.
3
Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. The Journal of clinical investigation. 2015;125(9):3335-3337.
4
Zheng P, Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in cancer. 2015;7(Suppl 2):15-18.
5
Sullivan RJ, Flaherty KT. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nature reviews Clinical oncology. 2015;12(11):625-626.
6
Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology. 2015;4(6):e1008853.
7
Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479-3492.
8
Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert opinion on therapeutic targets. 2015;19(2):201-211.
9
Noorbala MT, Mohammadi S, Noorbala M. Cutaneous malignant melanoma in central iran: a 20-year study. Iranian Red Crescent medical journal. 2013;15(8):690-694.
10
Noormohammadpour P, Ehsani A, Mirshams Shashahani M, Shahmohammadi F, Gholamali F. [Demographic and clinical characteristics of patients with malignant melanoma attending a referral skin tumors clinic in Iran: A 5-year study] (In Persian). Dermatology and Cosmetics. 2014;5(1):9-15.
11
Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. Journal of medicine and life. 2014;7(4):572-576.
12
Meng XJ, Ao HF, Huang WT, Chen F, Sun XC, Wang JJ, et al. Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma. BMC cancer. 2014;14:608.
13
Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1356-1364.
14
Plym A, Ullenhag GJ, Breivald M, Lambe M, Berglund A. Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: A population-based cohort study. Acta oncologica. 2014;53(5):688-696.
15
Patel F, Wilken R, Burrall B, Martinez S, Wells V, King B, et al. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines. Dermatology online journal. 2014;20(11).
16
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, 3rd, Daud A, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(4):395-407.
17
Pembrolizumab PI 2015. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf, Retrieved on 28 November 2015.
18
Nivolumab PI 2015. Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf, Retrieved on 28 November 2015.
19
Barnhart C. Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the advanced practitioner in oncology. 2015;6(3):234-238.
20
Marriott E, Praet C, Aguiar-Ibanez R, Pellissier J, Xu R, Wang J. Cost-Effectiveness of Pembrolizumab for Unresectable Metastatic Melanoma After Progression with Ipilimumab in England. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A453.
21
Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA dermatology. 2015:1-7.
22
Improta G, Leone I, Donia M, Gieri S, Pelosi G, Fraggetta F. New developments in the management of advanced melanoma - role of pembrolizumab. OncoTargets and therapy. 2015;8:2535-2543.
23
Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert review of anticancer therapy. 2015;15(9):981-993.
24
Kumar SS, McNeil CM. Pembrolizumab for the treatment of melanoma. Expert review of clinical pharmacology. 2015;8(5):515-527.
25
Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of clinical pharmacy and therapeutics. 2015.
26
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2015;16(8):908-918.
27
Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug design, development and therapy. 2015;9:2883-2886.
28
Sullivan RJ, Flaherty KT. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(13):2892-2897.
29
Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert opinion on drug safety. 2015;14(6):957-964.
30
Bohensky M, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost Effectiveness Analysis of Nivolumab Compared to Ipilimumab for the Treatment of Braf Wild-Type Advanced Melanoma in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A340.
31
Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of hematology & oncology. 2015;8(1):123.
32
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber J. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015.
33
Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert review of anticancer therapy. 2015;15(10):1135-1141.
34
Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, et al. Nivolumab in the treatment of malignant melanoma: review of the literature. OncoTargets and therapy. 2015;8:2045-2051.
35
Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention : APJCP. 2005;6(3):359-363.
36
Hosseini M, Seyed Alinaghi SA, Adimi Naghan P, Karimi S, Bahadori M, Khodadad K, et al. A Clinicopathologic Study of Lung Cancer Cases in Iran. Tanaffos. 2009;8(3):28-36.
37
Pirker R. Adjuvant chemotherapy of non-small cell lung cancer. Tanaffos. 2012;11(1):12-17.
38
Attarian H, Rezvani H, Ghadyani M, Eshaghi F. Consolidation chemotherapy with docetaxel after platinum-based chemotherapy in patients with non-small cell lung cancer: a preliminary report. Tanaffos. 2011;10(3):20-23.
39
Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2015.
40
Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015.
41
Pennell NA. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Seminars in oncology. 2015;42 Suppl 2:S3-S10.
42
Socinski MA. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. Seminars in oncology. 2015;42 Suppl 2:S19-28.
43
Garon EB. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Seminars in oncology. 2015;42 Suppl 2:S11-18.
44
Printz C. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer. Cancer. 2015;121(20):3562-3563.
45
Rice SJ, Miller B, Wagman M, Jamorabo DS, Liu X, Belani CP. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives. Current molecular pharmacology. 2015.
46
Waqar SN, Morgensztern D. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert review of clinical immunology. 2015;11(8):871-873.
47
Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(5):976-984.
48
Socinski MA. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. Seminars in oncology. 2015;42 Suppl 2:S1-2.
49
Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(21):6682-6687.
50
Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ. Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Human vaccines & immunotherapeutics. 2015;11(5):1201-1208.
51
Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. Journal for immunotherapy of cancer. 2015;3:15.
52
Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29(6):1441-1444.
53
Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. American journal of clinical oncology. 2015;38(4):422-430.
54
Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015.
55
Ascierto PA, Marincola FM. 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. EBioMedicine. 2015;2(2):92-93.
56
Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and therapy. 2015;8:929-937.
57
Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(17):3969-3976.
58
Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical therapeutics. 2015;37(4):764-782.
59
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(9):4275-4280.
60
Ipilimumab PI 2015. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf, Retrieved on 28 November 2015.
61
Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariepy J. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Molecular therapy Nucleic acids. 2015;4:e237.
62
Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(12):2965-2970.
63
Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer research. 2013;73(1):128-138.
64
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
65
Immunoscore Project 2015. Available from: (http://www.sitcancer.org/about-sitc/initiatives/immunoscore, Retrieved on 18 November 2015.
66
Henson SM, Macaulay R, Riddell NE, Nunn CJ, Akbar AN. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. European journal of immunology. 2015;45(5):1441-1451.
67
Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for immunotherapy of cancer. 2014;2:3.
68
Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. Journal of immunology. 2013;191(12):6060-6070.
69
Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nature reviews Immunology. 2014;14(11):768-774.
70
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013;369(2):134-144.
71
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012;366(26):2455-2465.
72
Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(21):3451-3457.
73
Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Laboratory investigation; a journal of technical methods and pathology. 2015;95(4):385-396.
74
Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer research. 2012;72(5):1070-1080.
75
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science translational medicine. 2013;5(200):200ra116.
76
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PloS one. 2015;10(6):e0130142.
77
Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. The Annals of pharmacotherapy. 2015;49(8):907-937.
78